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ABSTRACT  
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that affects 5.4 
million Americans. AD leads to memory loss, changes in behavior, and death. The key 
hallmarks of the disease are amyloid plaques and tau tangles, consisting of amyloid-β 
oligomers and hyperphosphorylated tau, respectively. 
Rho-associated, coiled-coil-containing protein kinase (ROCK) is an enzyme that plays 
important roles in neuronal cells including mediating actin organization and dendritic 
spine morphogenesis. The ROCK inhibitor Fasudil has been shown to increase learning 
and working memory in aged rats, but another ROCK inhibitor, Y27632, was shown to 
impair learning and memory. I am interested in exploring how these, and other ROCK 
inhibitors, may be acting mechanistically to result in very different outcomes in treated 
animals. 
Preliminary research on thirteen different ROCK inhibitors provides evidence that while 
Fasudil and a novel ROCK inhibitor, T343, decrease tau phosphorylation in vitro, 
Y27632 increases tau phosphorylation at a low dose and decreases at a high dose. 
Meanwhile, novel ROCK inhibitor T299 increases tau phosphorylation at a high dosage. 
Further, an in vivo study using triple transgenic AD mice provides evidence that Fasudil 
improves reference memory and fear memory in both transgenic and wild-type mice, 
while Y27632 impairs reference memory in transgenic mice. Fasudil also decreases tau 
phosphorylation and Aβ in vivo, while Y27632 significantly increases the p-tau to total 
tau ratio. 
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CHAPTER 1 
ALZHEIMER'S DISEASE AND RHO KINASE INHIBITORS 
Alzheimer’s disease 
 Alzheimer’s disease (AD) is a progressive neurodegenerative disease that results 
in memory loss, behavioral changes, and deficits in thinking and language skills. There is 
no definitive test that can be used to diagnose a person with AD, and a final confirmation 
post-mortem is necessary to determine whether a person did suffer from AD. A physician 
must diagnose the disorder with a thorough medical examination that can include medical 
history, mental status testing, physical exams, blood tests, and brain imaging. Some of the 
testing required is used to rule out other dementias. Although AD is not easy to diagnose, 
it affects 5.4 million Americans and is the 6th leading cause of death in the United States. 
AD accounts for 60-80% of dementia cases, with the yearly socioeconomic cost of AD 
estimated at approximately $221.3 billion in 2015 (Gaugler, James, Johnson, Scholz, & 
Weuve, 2016).  
 In the decade between 2000 and 2010, the top five causes of death in the United 
States showed decreases in mortality rates due to increased awareness of early diagnoses, 
better therapeutic options, and preventative care (Kochanek, Murphy, Xu, & Tejada-
Vera, 2016). Meanwhile, AD, ranked as the 6th leading cause of death, showed a 68% 
increase in mortality rates due longevity of people in the United States, coupled with 
continued lack of early diagnosis, preventative options, and therapeutics.  
 The first clinical signs of AD include deficits in episodic and spatial memory, 
followed by deficits in working memory, and in late stages of the disease, long-term 
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memory. The behavioral hallmark of AD also includes the inability for patients to form 
new memories.  
 Clinically, AD can be divided into two groups, early onset and late onset. 
Development of AD before the age of 60 is often considered early onset, whereas after 60 
years of age is considered late onset. Early onset AD has been characterized as familial, 
with autosomal dominant mutations in amyloid precursor protein (APP), presinilin 1 
(PS1), and presinilin 2 (PS2). Despite this, the vast majority of AD cases are late onset, 
and develop sporadically without a clear genetic component. The primary risk factor for 
AD is aging, with approximately 20% of people between 75-84 years of age and 50% of 
people 85 years and older suffering from the disorder. Additional risk factors include, 
family history of AD, carrying the apolipoprotein E (APOE)-e4 gene (Naj et al., 2014), 
and traumatic brain injury (Sennik, Schweizer, Fischer, & Munoz, 2016).  
 Current treatment options for AD include only five drugs—four cholinesterase 
inhibitors and Memantine (Szeto & Lewis, 2016). Cholinesterase inhibitors prevent the 
breakdown of acetylcholine, which is a key chemical messenger for learning and 
memory. Cholinesterase inhibitors are prescribed to patients with mild to moderate AD 
(Birks, 2006). However, the evidence suggests that these drugs do not slow the 
progression of dementia over time. Memantine is an N-mehtyl-D-aspartate receptor 
antagonist, and regulates glutamate activity, which is also involved in learning and 
memory. Memantine is prescribed in moderate to severe stages of AD, and there has been 
some evidence suggesting that Memantine may have neuroprotective potential (Danysz & 
Parsons, 2003). It can also be used in conjunction with a cholinesterase inhibitor. These 
drugs, however, are only symptomatic treatments, and do not affect the pathophysiology 
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underlying AD.  Furthermore, they do not alter the course of the disease, and the relief 
they provide is relatively short-lived.  
As the “baby-boomer” generation ages and enters the average age at which late 
onset AD is clinically determined to be the cause of memory problems, the number of 
people who are susceptible to AD will increase dramatically. This year, the first baby 
boomer will turn 65 years old. The Alzheimer’s Association predicts an increase from 5.4 
million to 10 million Americans with AD by 2030. Without adequate early biomarkers 
and treatments for AD, the cost of AD will also skyrocket. 
Instead of the traditional approach in treating AD, in which therapy begins after 
patients develop memory problems and cognitive deficits, preventative measures may 
lead to better outcomes, ultimately lowering the prevalence of the disease. 
Neurobiologists, with the support of the FDA, are working toward the identification of 
early biomarkers for AD and subsequent development of preventative therapeutics, 
including tools to decrease amyloid plaque formation and neurofibrillary tangle (NFT) 
formation, as well as tools to enhance declining cognitive function in AD patients 
(Anand, Gill, & Mahdi, 2013; Tayeb, Yang, Price, & Tarazi, 2012)  
 
Neuropathology 
AD is characterized by atrophy of the cortex, including enlarged ventricles and 
gyral shrinkage, along with the presence of two hallmark biomarkers, intracellular 
neurofibrillary tangles composed of hyperphosphorylated microtubule-associated protein 
tau, and extracellular plaques composed of amyloid-ß (Aß). The accumulation of these 
misfolded proteins results in oxidative and inflammatory stress, leading to both energy 
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failure and synaptic dysfunction. Furthermore, proper diagnosis of AD typically requires 
post-mortem histological confirmations of both plaques and tangles. Thus, it is noted that 
both the pathology of tau and Aß likely play a key role in the pathogenesis of the disease.  
 
Aß 
AD was first diagnosed by Alois Alzheimer in 1906, when he observed amyloid 
plaques in a woman with progressive dementia (Cipriani, Dolciotti, Picchi, & Bonuccelli, 
2011). Amyloid plaques are composed mostly of Aβ peptides, which consist of 36 to 43 
amino acids derived from the amyloid precursor protein (APP). APP, in turn, is encoded 
by the APP gene located on chromosome 21 (Yoshikai, Sasaki, Doh-ura, Furuya, & 
Sakaki, 1991). The protein APP is a type 1 transmembrane protein consisting of 695-770 
amino acids. Aß is produced as a monomer but aggregates to form multimeric complexes. 
The severity of cognitive symptoms in AD  does not correlate with the amount of Aß in 
the brain, but instead, is correlated with the levels of oligomers in the brain (Takahashi, 
Nagao, & Gouras, 2017). There is no conclusive evidence regarding the normal 
functionality of Aβ, or whether the total loss of Aβ would cause detrimental effects—in 
animal studies, physiological function does not seem to be affected (Phinney et al., 1999); 
however, they may be involved in the activation of kinase enzymes, serve as protection 
against oxidative stress, or play a role as a transcription factor, among other possibilities.  
APP is processed into Aß through a multi-step process. First, full-length APP is 
cleaved by either - or -secretase, to produce two large soluble fragments, sAPP or 
sAPPß, and two membrane-anchored C-terminal fragments, CTF or CTFß, respectively. 
The C-terminal fragments are then processed by -secretase to generate either P3 peptide 
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or Aß peptides, along with the APP intracellular domain fragment (Zhang, Thompson, 
Zhang, & Xu, 2011). Aß plaques are composed mostly of Aß40 and Aß42, predominantly 
with the latter, which is the isoform of Aß with an extended C-terminal, and is insoluble, 
while Aß40 is relatively soluble. That said, Aß40 has been shown to significantly increase 
in concentration in the AD brain (Näslund et al., 1994) as well.   
The Aß cascade hypothesis proposed by Hardy and Selkoe suggests that the 
accumulation of extracellular Aß aggregates, or senile plaques as an outcome of those 
aggregates, catalyzes the cascade of neurotoxic events that lead to neurodegeneration in 
AD. These neurotoxic events include the facilitation of tau phosphorylation, disruption of 
proteasome and mitochondria function, dysregulation of calcium homeostasis, 
impairment of synaptic function, inhibition of long-term potentiation, and neuronal death.  
 
Tau 
Tau is a microtubule-associated protein that is essential for microtubule assembly 
and stability (Drechsel, Hyman, Cobb, & Kirschner, 1992; Lindwall & Cole, 1984; 
Trinczek, Biernat, Baumann, Mandelkow, & Mandelkow, 1995). Tau is highly expressed 
in neurons, with low levels of tau expression also found in astrocytes and 
oligodendrocytes (Binder, Frankfurter, & Rebhun, 1985; LoPresti et al., 1995). 
Microtubule Associated Protein Tau (MAPT) is a gene that encodes for six different 
isoforms of tau found in the adult human brain through alternative mRNA splicing. 
MAPT consists of 16 exons on chromosome 17q21, and transcription is differentially 
expressed through the nervous system based on the stage of neuronal maturation and 
type. While mutations in the MAPT gene are not linked to AD, studies have shown a 
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correlation between MAPT haplotype variants and AD risk (Myers et al., 2005; Randall 
et al., 2009). 
 Tau function is highly regulated by post-translational modifications, including the 
addition and removal of phosphate groups through the activity of several phosphates and 
kinases. There are 79 potential serine (Ser) and threonine (Thr) residues in the longest tau 
isoform that are able to act as phosphate acceptor sites. Phosphorylation at approximately 
30 of these sites has been confirmed in normal tau proteins. Tau phosphorylation is 
developmentally regulated and the degree of phosphorylation in each of the isoforms 
increases with age. While some phosphorylation sites associated with AD are found in 
the healthy brain as well, there are also many phosphorylation sites that are found only in 
the AD brain. 
 An increase in tau phosphorylation decreases the binding of microtubules. 
Hyperphosphorylated tau is insoluble, and is unable to dephosphorylate or bind 
microtubules. Hyperphosphorylated tau self-associates into paired-helical filament, which 
congregate to create neurofibrillary tangles. Intermediate aggregates of abnormal tau 
molecules are cytotoxic and impair cognition. The levels of phosphorylated and total tau 
in cerebrospinal fluid inversely correlate with scores on cognitive exams and could serve 
as a biomarker for pathology progression.  
 
Dual Pathway Hypothesis 
The dual pathway hypothesis supports the view that Aß plays a large role in the 
pathogenesis of AD; however, it is apparent that Aß is not the sole driving factor of AD, 
therefore, warranting further investigation in uncovering additional components driving 
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the pathology. For example, in a phase 1 study immunizing AD patients against Aß, post 
mortem results confirmed a decrease in both amyloid and plaques; however, there was no 
change in survival rates, or in latency and severity of end stage dementia (Holmes et al., 
2008; Weller & Nicoll, 2003). Thus, the dual pathway hypothesis suggests that upstream 
factors drive both Aß and tau pathology. That said, treating downstream effectors of 
either of these pathologies would not be an effective treatment strategy.  
Many studies to date have been targeting the investigation of either amyloid 
pathology, or tau pathology. Targeting tau pathology takes several forms, including the 
prevention of the phosphorylation of tau, prevention of the misfolding of tau, prevention 
of the aggregation of tau, and tau immunotherapy. However, it may be more beneficial to 
target both amyloid and tau pathologies simultaneously.  
 
Rho-associated protein kinase 
RhoA is a small GTPase that works through Rho-associated protein kinase 
(ROCK) to mediate actin organization and cellular migration. ROCK has two isoforms, 
ROCK I and ROCK II. While both isoforms are similar in both amino acid sequence and 
kinase domains, they differ in expression. ROCK I is found mostly in non-neuronal 
tissues such as the stomach, liver, spleen, kidneys, and testis. Meanwhile, ROCK II is 
found mostly in the brain and muscle tissues.  
 
ROCK Inhibitors: Fasudil and Y27632 
There are two main methods for treatment of disease: small, chemically 
manufactured molecules (SMOLs) and monoclonal antibodies. SMOLs constitute the 
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majority of pharmaceuticals. The major advantage that SMOLs have over antibodies is 
that SMOLs are absorbed when administered orally, although this is not always the case.  
Fasudil is a SMOL ROCK inhibitor of both ROCK I and ROCK II isoforms, to 
varying degrees (Table 1). Fasudil has been widely used in Japan since 1995 as a 
treatment for cerebral vasospasms occurring after a subarachnoid hemorrhage, and has 
since also become clinically available in China (Feng, Lograsso, Defert, & Li, 2016). 
ROCK increases angiotensin-converting-enzyme (ACE) activity, which then increases 
the conversion of angiotensin I to angiotensin II, a peptide hormone that increases blood 
pressure. Fasudil decreases the amount of ACE and thereby angiotensin II, leading to a 
decrease in blood pressure and improves cerebral vasospasms. The ROCK pathway has 
been under investigation as playing a key role in several different diseases, including 
neurodegenerative diseases such as Parkinson’s disease and amyotrophic lateral sclerosis. 
There is evidence that shows Fasudil treatment in a Parkinson’s mouse model has 
protective effect on the mice, both in neurons and learning and memory behavior (Tönges 
et al., 2012). 
 Fasudil has been demonstrated to have neuroprotective effects on both murine 
models and humans. Studies have also reported a protective effect against injury to 
neurons after cerebral ischemia (S. Satoh et al., 1996; S. I. Satoh et al., 2001; Toshima, 
Satoh, Ikegaki, & Asano, 2000) and hypoxia-reoxygenation in mouse models (Ding et al., 
2010; Jing D, Qin-Ying L, Xin W, Chang-Hai S, Chuan-Zhen L, 2010). Furthermore, 
Fasudil treatment in humans within 48 hours of acute ischemic stroke has been shown to 
have significant improvement in clinical outcomes. In addition, Fasudil has shown to 
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have a neuroprotective effect via suppression of an inflammatory response in 
autoimmune encephalomyelitis.  
Y27632, another ROCK inhibitor, inhibits both ROCK I and ROCK II by 
competing with ATP by binding to the catalytic site of the kinase. Inhibition of ROCK is 
selective, and Y27632 does not significantly inhibit other kinases such as PKC, MLCK, 
and cAMP-dependent protein kinases. Y27632 is cell permeable (Ishizaki et al., 2000) 
via a carrier-mediated facilitated diffusion into the cell. Y27632 has also been shown to 
affect brain structures when administered via drinking water (Abouhamed et al., 2009) or 
intraperitoneal injections (Inan & Büyükafşar, 2008).  
   
ROCK and AD 
The KIBRA gene was associated with variation in normal episodic memory 
performance in adults (Papassotiropoulos et al., 2006) via a 500K single nucleotide 
polymorphism genome-wide associate study. There has also been evidence suggesting a 
genetic link between KIBRA variation and Alzheimer’s disease (Corneveaux et al., 
2010). KIBRA is a substrate for PKCζ (Büther, Plaas, Barnekow, & Kremerskothen, 
2004) and has been shown to interact with Dendrin, a postsynaptic cytoskeleton 
modulatory molecule. The ROCK pathway is upstream of PKCζ (Kampfer et al., 2001; 
Scott, Arioka, & Jacobs, 2007; Uberall et al., 1999; Van Kolen & Slegers, 2006), and 
could therefore have an effect on cognition in both the healthy and AD populations as 
well. Along with this, the inhibition of ROCK can potentially be an effective therapeutic 
for AD through the prevention of tau hyperphosphorylation, and amyloid plaques, or 
through generally improved cognition.  
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An early case study reported the effects of Fasudil treatment on cerebral 
vasospasm patients (Kamei, Oishi, & Takasu, 1996), in which two patients with 
cerebrovascular dementia exhibiting wandering symptoms and forgetfulness were treated 
with Fasudil for 8 weeks at 30 mg/kg or 60 mg/kg. Results showed that patient memory 
was slightly improved and their wandering symptoms disappeared during Fasudil 
treatment, reappearing a few days following treatment.  
Fasudil has also been reported to decrease learning and memory deficits and 
attenuate neuropathology in rats injected with streptozotocin in order to produce synaptic 
dysfunction similar to that found in the early stages of AD (Hou, Zhou, Yang, Du, & Li, 
2012).  Fasudil-treated rats not only showed improvement on the Morris water maze, but 
they also had increased expression levels of SYP, which plays a key role in synapse 
number and plasticity. Fasudil treatment also attenuated the increased phosphorylation of 
both LIMK and cofilin due to the streptozotocin injection. Furthermore, Fasudil has been 
reported to improve cognition and attenuate neuropathology in rats injected with Aß42 
into the left lateral ventricle (Song, Chen, Wang, Gao, & Zhu, 2013). Rats treated with 
Fasudil improved on the Morris water maze and had decreased neuronal injury in the 
hippocampus.  
Fasudil has been tested as a cognitive enhancer in aged rats. Wild-type aged rats 
were treated with Fasudil and tested on the Morris water maze. The results showed that 
the Fasudil-treated rats had increased learning and memory scores on the maze in 
comparison to vehicle-treated rats (Huentelman et al., 2009). 
ROCK inhibitor Y27632 has been tested on ischemic and wild-type rats as a 
cognitive enhancer (Castro-Alvarez, Gutierrez-Vargas, Darnaudéry, & Cardona-Gómez, 
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2011). Y27632 treatment in ischemic rats led to an improvement in learning and memory 
scores; however, in normal rats, Y27632 treatment led to a decrease in learning and 
memory scores.  
 Inhibition of ROCK has been shown to in turn inhibit cyclin dependent kinase 5 
(Cdk5), a regulator of cell differentiation and morphology that has been well established 
as an important kinase in the pathology of AD (Cho et al., 2013; Chu, Li, & Praticò, 
2013; Flaherty, Soria, Tomasiewicz, & Wood, 2000; Shukla, Skuntz, & Pant, 2012). 
Aberrant activation of Cdk5 leads to tau hyperphosphorylation and NFT deposition. 
ROCK may affect AD risk through its effect on Cdk5 (Castro-Alvarez et al., 2011), 
implying that ROCK inhibition would inhibit Cdk5, leading to tau phosphorylation 
inhibition and decreased risk of AD. 
 Nonsteroidal anti-inflammatory drugs (NSAIDs) have been reported to decrease 
Aß42 in vitro. While some studies have suggested that this is due to the effects NSAIDs 
have on cyclooxegenase, others have shown that NSAIDs decrease Aß42 in the absence of 
cyclooxegenase activity. One hypothesis is that NSAIDs affect Aß42 levels through the 
Ras family of proteins, including ROCK. Inhibition of Rho has been shown to decrease 
Aß42 concentrations in vitro (Zhou et al., 2003). Further, it showed that application of 
ROCK inhibitor Y27632 reduced Aß42 in a concentration-dependent manner in vitro, and 
lowered cortical Aß42 in Parkinson’s disease APP mice injected with Y27632.  
ROCK inhibits myosin light chain (MLC) phosphatase, which acts on acto-
myosin interactions and on MLC (Kawano et al., 1999), both of which have been 
associated with synaptic plasticity (Hayashi et al., 1996; Lamprecht, Farb, & LeDoux, 
2002; Lamprecht & LeDoux, 2004). ROCK inhibition in a non-diseased brain, therefore, 
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would deregulate MLC phosphatase, decreasing both MLC and acto-myosin interactions, 
diminishing the capacity for synaptic plasticity and learning. However, in an excitotoxic 
state, typically seen as a constant in the AD brain, MLC has been shown to be overactive, 
causing disruptions in synapses and decreasing learning. A ROCK inhibitor used in that 
state could decrease MLC, and stabilize synapses to increase cognition.  
 ROCK has also been found to increase Phosphatase and tensin homolog deleted 
on chromosome 10 (PTEN) and Akt activity (Wu et al., 2012), thereby reducing the 
phosphorylation of Glycogen synthase kinase-3 beta (GSK-3β). Due to GSK-3β 
inhibition through phosphorylation has been previously shown to decrease p-tau in the 
AD brain (Flaherty et al., 2000; Hamano, Yen, Gendron, Ko, & Kuriyama, 2012), and 
ROCK inhibition has been shown to maintain phosphorylation of GSK-3β (Castro-
Alvarez et al., 2011), ROCK inhibition should therefore also reduce p-tau. Consequently, 
decreased levels of p-tau would lead to decreased NFT. 
 However, ROCK phosphorylates LIM kinase (LIMK) (Maekawa, 1999), which in 
turn phosphorylates cofilin and is crucial in F-actin stabilization (Munsie & Truant, 2012; 
N. Khan, 2012; Y. Wang et al., 2013), both of which are important factors in learning and 
memory. LIMK has also been associated with CREB phosphorylation and the subsequent 
neurogenic factor-induced neuronal differentiation in CNS hippocampal progenitor cells - 
a critical task for memory formation (Blum, Moore, Adams, & Dash, 1999). This 
pathway could prove deleterious for learning and memory when a ROCK inhibitor is 
applied, as synaptic plasticity and neuronal differentiation may decrease. However, 
during excitotoxic events, overactivation of ROCK causes high cytoskeletal 
reorganization, leading to irreversible neuronal disconnection and cell death (Esposito et 
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al., 2013; Salińska, Danysz, & Łazarewicz, 2005). ROCK inhibitors could reverse the 
effects of excitotoxicity, a prevalent factor in AD. 
 
Modeling AD  
in vitro 
When selecting an in vitro methods of modeling AD, there are a multitude of 
options that include 3D culture, organotypic brain slice cultures, induced pluripotent stem 
cells, and cells that have been transfected to overproduce APP or tau proteins.  
For an initial screening of drugs with a hypothesis of decreased phosphorylation 
of tau, however, 3D culture, organotypic brain slices, and induced pluripotent stem cells 
are not efficient or cost-effective. Using a cell line that is transfected to overproduce tau 
is the most efficient option to test whether drug treatment would improve tauopathy. The 
cell line selected was the H4 neuroglioma cells overexpressing four repeat tau (4R0N), or 
H4-tau cells. H4-tau cells are transfected to overproduce tau, and are a standard in the 
AD field as a model for tauopathy in AD. It is necessary to use this cell line to produce 
sufficient levels of phosphorylated tau for significant detection. 
in vivo 
 There are many in vivo models for AD, made up for the most part by mouse 
models. There are both transgenic and non-transgenic mouse models of AD. Non-
transgenic mouse models are mice that have direct infusions of Aβ or tau into different 
areas of the brain, depending upon the model. Transgenic mouse models are more 
commonly used as models of AD. These include a multitude of single transgenic mice as 
well as multi-transgenic mice.  
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Single transgenic models 
 There are several transgenic models with APP mutations. Some have mutations at 
the β-secretase cleavage site (Tg2576(Swe)), some have mutations at the gamma-
secretase cleavage site (PDAPP(Indiana)), and some have mutations within the Aβ 
sequence (TgAPParc, APPDutch). These models have Aβ plaques, but no neurofibrillary 
tangles. They do have synaptic and memory deficits that generally precede the plaques. 
There are also higher levels of diffuse amyloid deposits compared to wild-type.  
 
Multi-transgenic models 
 APP/PS1 mice are a bigenic AD mouse model that were produced using the APP 
Swedish and PSEN1 L166P mutations, both under the control of the Thy1 promoter. The 
expression of human APP is 3-fold higher than the endogenous APP in this mouse model. 
Aβ deposits begin at 6 weeks of age in the cortex. By 4 months of age, Aβ deposits are 
also found in the hippocampus. While some phosphorylated tau processes have been 
found around plaques in this mouse model, there have been no mature tangles. APP/PS1 
mice tested in the Morris water maze have been shown to have diminished spatial 
learning and memory at 7 months of age, and at 8 months of age, the mice have shown 
diminished learning in a food-rewarded spatial maze task. 
 APPSwe-Tau mice are a bigenic AD mouse model that were produced by 
crossing Tg2576 mice with JNPL3 mice. These mice develop significant levels of plaque 
pathology and neurofibrillary tangles respectively. The mutations used in the progenitor 
mice are APP Swedish and MAPT P301L. Plaques develop gradually starting at 
approximately 6 to 7 months of age, with none found at 5 months. By 9 months of age, 
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plaques are scattered throughout the brain including the cortex, hippocampus, and 
amygdala. There is a significantly higher number of plaques at 12 months of age than at 9 
months of age, indicating a continued increase of plaques over time. Meanwhile, some 
neurofibrillary tangles are found as early as 3 months in the spinal cord and pons. 
However, the tangles are more consistently found by 6 months of age. Female mice had 
an increase in tangles in the olfactory cortex, entorhinal cortex, and amygdala by 6 
months of age as well.  
Triple transgenic AD (3xTg-AD) mice are widely regarded as a reliable model of 
AD. These mice express exogenous mutations in APP and tau, as well as an endogenous 
familial mutation in presinilin associated with familial AD, making it a desirable model 
for phenotyping AD. The mutations are APP Swedish, MAPT P301L, and PSEN1 
M146V. To produce these transgenic mice, single cell embryos of mice with the knock-in 
of the PSEN1 mutation were injected with the human transgenes for the APP and MAPT 
mutations. The transgenes are integrated at a single locus under the control of the Thy1.2 
promoter.  
The overexpression of these transgenes produce progressive AD plaque and 
tangle pathology. Aß deposition increases over time, and intracellular deposits can be 
seen as early as 4 months of age in the neocortical region. Extracellular deposits can be 
detected by 6 months of age in the frontal cortex and CA1 pyramidal neurons, and this 
becomes more extensive as the mice age. By 12 months of age, Aß deposits spread to 
other hippocampal regions as well as other cortical regions. Tau hyperphosphorylation 
starts later, beginning with tau being phosphorylated at Ser202, Thr205, and Thr231 sites 
at 12 months. Paired helical filaments and tangles can also be detected in the 
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hippocampus at approximately 12 months of age. By 18 months of age, late stage 
phosphorylation sites, Ser396 and Ser404 are also hyperphosphorylated. Tau pathology 
spreads from the hippocampus, especially within the CA1 pyramidal neurons, to the 
cortical structures over this course of time. 3xTg-AD mice were also shown to manifest 
cognitive impairment beginning at 4 months of age (Billings, Oddo, Green, McGaugh, & 
LaFerla, 2005; Oddo et al., 2003).  
The present study utilized 3xTg-AD mice and their wild-type complement, 
C57BL/6. Only female mice were used due to the higher variability in phenotype found 
in male 3xTg-AD mice. 
 
Learning and Memory Behavior Tests 
A variety of cognitive behavioral tests are available to assess learning and 
memory in mice. Because AD pathology originates and is most severe in the 
hippocampus, hippocampal-dependent learning and memory tests are the most relevant in 
studying the efficacy of a treatment. The three behavioral tasks most commonly used to 
assess learning and memory in mice modelling AD are the Morris water maze, the radial 
arm water maze, and the fear conditioning test (Puzzo, Lee, Palmeri, Calabrese, & 
Arancio, 2014). 
 
Morris Water Maze 
The Morris water maze is a learning and memory task created by Dr. Richard 
Morris in 1981 (Morris, 1981). Briefly, the Morris water maze is a spatial learning task 
that uses a large circular tub filled with opaque water. A small platform is placed in one 
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quadrant of the tub, and is not moved from that spot. The mouse is placed in one of the 
non-platform quadrants and recorded as she swims for up to 60 seconds, with recording 
ending early if she finds the platform. There are extra-maze cues that the mouse can use 
to find the platform. Data is accumulated for each trial, and can be analyzed in several 
ways. The amount of time spent searching for the platform and the distance swam 
searching for the platform can both be analyzed for each trial, to determine whether the 
time and distance decrease with each trial. If the mouse is learning, they should decrease. 
These variables can also be analyzed for only the first trial of each day. This is called 
overnight retention, and can be informative for whether the mouse has retained the 
information learned from the previous day. This can be considered long-term memory. 
Finally, on the last day of the task, the platform is removed and the mouse is recorded 
swimming for 60 seconds for a probe trial. The amount of time spent in the platform 
quadrant and the opposite quadrant are measured, along with the number of times the 
mouse crosses the space in which the platform was previously. The more time spent in 
the platform quadrant, and the higher number of platform crossings is considered 
evidence that the mouse has retained spatial memory. Longer time spent in the opposite 
quadrant is considered evidence that the mouse has impaired spatial memory. 
The Morris water maze is widely used due to the lack of food deprivation or 
electric shock as motivators. The task uses the animal’s dislike of water as a motivator 
instead. However, there are some weaknesses. Some mice will swim in circles, remaining 
close to the edge of the tub, increasing the amount of time spent “looking for the 
platform”, when in fact the mouse is not doing so. Some of the variance in performance 
scores in the Morris water maze may be due to differences in thigmotaxis, the tendency 
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for animals to stay close to walls, rather than to differences in spatial memory. 
Thigmotaxis is seen significantly more in female rodents (Devan, Tobin, Dunn, & 
Magalis, 2016). Mice are more affected by not only thigmotaxis (Gerlai & Clayton, 
1999), but also passivity, or the tendency to float (Vorhees & Williams, 2006; Whishaw 
& Tomie, 1997), in comparison to rats. Some mice also will float passively in the water 
until “rescued” by the experimenter—this variability was decreased by decreasing the 
water temperature to increase aversion to the environment (Lipp & Wolfer, 1998) and 
when that failed, issuing a loud sound when a mouse floated for longer than five seconds 
without movement. While this is not a perfect task measuring spatial memory, it is widely 
used and informative in testing hippocampal-dependent spatial learning. 
 
Radial Arm Water Maze 
The radial arm water maze is a learning and memory task created by Drs. Olton 
and Samuelson in 1976 (Olton & Samuelson, 1976). Reference memory and working 
memory are both assessed during this task, and can be measured by keeping track of two 
separate types of incidents. Working memory is a short-term memory process that allows 
for temporarily holding information to guide behavior (Buresova, Bures, Oitzl, & 
Zahalka, 1985). Briefly, the task consists of an eight-arm maze radiating from a circular 
central area. One arm is the “goal arm” and includes a small platform at the end. Extra-
maze cues are placed for the mouse to use to find the platform. The mouse is placed in 
the maze from any of the non-goal arms and the time the mouse takes to find the 
platform, as well as the number of times the mouse enters each of the incorrect arms is 
counted. The total number of times a mouse enters incorrect arms prior to reaching the 
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platform, or to the end of the timed trial, is used to measure reference memory. The 
number of times a mouse re-enters incorrect arms prior to reaching the platform, or the 
end of the timed trial, is used to measure working memory. If a mouse re-enters the 
incorrect arm many times even though the platform was not there during previous 
attempts, the mouse is considered to have poor working memory. The radial arm water 
maze has been used to test working memory in a variety of AD mouse models, and has 
been shown to detect impairment in mutant tau mice (Arendash et al., 2006; Golub et al., 
2008; Rees et al., 2005) and in mutant APP mice (Volianskis, Køstner, Mølgaard, Hass, 
& Jensen, 2010; Xiong et al., 2011).  
 
Fear Conditioning 
While the Morris water maze and the radial arm water maze are both spatial 
memory oriented tasks, fear conditioning tests whether an animal learns to predict 
aversive events. The amygdala is largely involved in the emotional formation and storage 
of memories, such as those involving fear (LeDoux, 2003); however, learning the context 
in which the fear inducing stimulus occurred largely involves the hippocampus (Phillips 
& LeDoux, 1992). Briefly, a mouse is placed in a novel chamber for three minutes and 
toward the end of the task, a light turns on and a shock is delivered to the mouse. The 
mouse is returned to her home cage, until the next day when she is placed back into the 
chamber. The number of times the mouse freezes, as well as the length of each freeze, is 
measured and analyzed. The sympathetic response to fear in rodents has been 
demonstrated as a defensive behavior represented by freezing. Freezing is a total absence 
of movement outside of breathing (Blanchard & Blanchard, 1969). Significantly 
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decreased amount of freezing behavior in comparison to the control is considered an 
impaired fear response, while increased freezing behavior is considered an improvement 
in fear response and memory. Patients with mild to moderate AD have exhibited impaired 
conditioned fear responses, and mouse models of AD have also exhibited impairment that 
worsens with age.  
 
Aims of Research 
I. in vitro drug selection: To better understand the effects of ROCK inhibitors 
on tau phosphorylation, thirteen different ROCK inhibitors were used to 
treat H4-tau cells at an LD-10 dosage over a 96-hour time course. Eight of 
these drugs were novel ROCK inhibitors, developed at TGen.  
A. Phosphorylated tau (S396) and total tau levels were measured at each 
time point for each treatment. The four final drug candidatees, Fasudil, 
Y27632, T299, and T343 were tested again at a higher dosage (LD-50) 
to validate results. 
B. RNA was collected from cells treated by the four drugs at the LD-50 
dosage. Next Generation Sequencing was performed to test for 
significant transcriptional changes in line with difference in the drug 
effects on the ratio of phosphorylated to total tau. 
II. in vivo drug testing: While Fasudil and Y27632 have previously been tested 
on learning and memory in rodent models, they have never been tested on 
triple transgenic Alzheimer’s disease (3xTg-AD) mice, and alongside one 
another. It is beneficial to test both drugs on the same model, and in the 
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same manner, to better parse out whether the differences in their effects are 
due to the different models or due to the drug mechanisms.  
A. ROCK inhibitors were administered via drinking water to both 3xTg-
AD and wild type mice. Vehicle treated animals were used as controls. 
Treatment began at 3 months of age, 1 month prior to literature based 
reports of pathology and significant cognitive deficits. Learning tasks 
were administered at 10 months, 12 months, and 15 months, critical time 
points for changes in pathology and behavior in 3xTg-AD mice. The 
total study period was 12 months. 
B. Neuropathology was conducted in post-mortem brain tissue following 
behavioral testing. Western blots were performed on protein extracted 
from the hippocampus to test for changes in APP and APP cleavage 
sites, total tau, and phosphorylated tau. Immunohistochemistry was 
performed to visualize differences in phosphorylated tau and Aβ42, 
which are indicative of tangle and plaque formation, in the hippocampus 
and the cortex. Finally, ELISAs were utilized to test for Aβ40 and Aβ42 
in both soluble and insoluble fractions in the hippocampus. 
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CHAPTER 2 
THE EFFECT OF ROCK INHIBITORS ON TAU PHOSPOHORYLATION: AN IN 
VITRO STUDY 
Abstract 
Rho kinase (ROCK) is an enzyme that plays an important role in neuronal cells. 
The ROCK inhibitor Fasudil has been shown to increase learning and working memory in 
aged rats, while another ROCK inhibitor Y27632 was shown to impair learning and 
memory in normal rats. These observations suggest different mechanisms of action 
underlying these ROCK inhibitors, albeit their structural differences. 
 Thirteen different ROCK inhibitors, five of which are commercially available and 
eight of which were newly designed and synthesized for this study, were used to treat 
human neuroglioma cell overexpression of 4-repeat tau (H4-tau) across a 96-hour time 
course, which was broken down into 8, 12-hour intervals:  12, 24, 36, 48, 60, 72, 84, and 
96 hours. The ratio of Serine 396 phosphorylated tau (p-tau) to total tau was measured 
using ELISA at each time point. All drug treatments were compared against the 
corresponding time point for vehicle-treated cells. Fasudil was the only commercially 
available drug to decrease the p-tau to total tau ratio. Of note, Y27632 did not decrease this 
ratio. In addition, several of the novel ROCK inhibitors significantly decreased the p-tau 
to total tau ratio. Of these, T343 had the greatest significance. T299, another newly 
designed ROCK inhibitor, displayed no change in the p-tau to total tau ratio despite its 
similarity to T343 in ROCK-I and ROCK-II inhibition. With an increased dosage, Fasudil, 
T343, and Y27632 were found to decrease the p-tau to total tau ratio, while T299 was found 
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to increase the ratio. These findings detail several drugs with a shared target with 
differential effects on tau. 
 Phosphorylation of tau at Serine 396 decreases tau mobility and the ability of tau 
to bind microtubules, contributing the tauopathy of Alzheimer’s disease. These results 
present a unique opportunity to utilize these molecules to dissect associated changes in p-
tau to total tau ratio, and tailor drugs to more effectively target p-tau. The differential 
effects of ROCK inhibitors on the p-tau to total tau ratio, as well as on learning and memory 
on healthy animals, are compelling. Further research is necessary to parse out whether the 
effects of Fasudil on learning and memory are mediated through changes in p-tau to total 
tau expression, or through other on- or off-target effects. 
 
Experimental Procedures 
Drugs 
Originally, 13 different ROCK inhibitors were screened. 8 of the 13 drugs were 
novel inhibitors designed at the Translational Genomics Research Institute and the rest 
were commercially available ROCK inhibitors. The drugs and their structures, molecular 
weights, and enzymatic inhibition of ROCK I and ROCK II are available in Table 1.  
The top 4 candidates selected based on the first round of in vitro experiments were 
Fasudil, Y27632, T343, and T299. Fasudil and Y27632 are commercially available ROCK 
inhibitors, while T343 and T299 are novel ROCK inhibitors. 
 
Cell Culture 
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H4-tau cells were used for this study. H4-tau cells are a standard use in the AD field 
as a model for tauopathy in AD. It is necessary to use this cell line to produce sufficient 
levels of tau and phosphorylated tau for detection of significant changes in those levels. 
Cells were maintained in Dulbecco’s Modified Eagle Medium (Invitrogen) supplemented 
with 10% fetal bovine serum, 1% geneticin (Invitrogen), and 25% HEPES (ThermoFisher). 
Cells were split at 80% confluency every two weeks until they were plated at 8x104 cells 
per well in 6-well plates (surface area = 9cm2).  
 
Protein extraction 
 Cells were lysed using 150ul of RIPA buffer and 10 ul Halt Protease Inhibitor 
Cocktail (Thermo Scientific). The plate was incubated on ice for one hour. Lysate was 
harvested into 1.5mL centrifuge tubes, and kept on ice. Each sample was then sonicated 
briefly at amp=1. Lysate was spun in the centrifuge at 10,000g for 15 minutes at 4C and 
supernatant was collected and transferred to a fresh tube, to be used in ELISAs.  
 
Determining the LD-10 value 
Viability assays were performed using a 96-well plate paradigm, with metabolic 
activity measured using alamar Blue (Invitrogen). 10% alamar Blue was added directly to 
H4-tau cells in Dulbecco’s Modified Eagle Medium (Invitrogen) supplemented with 10% 
fetal bovine serum (Invitrogen), 1% Geneticin (Invitrogen), and 25% HEPES. This assay 
works based on the ability of metabolically active cells to convert alamar Blue reagent into 
a fluorescent signal, proportional to innate metabolic activity. The LD-50 value was 
determined using curve fitting statistics, and the LD-10 value was determined from there. 
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Performing a 96-hour time course 
Each drug was applied to H4-tau cells in a 6-well plate. Cells were plated at 8x104 
cells per well in normal growth media as described in 2.2. After 24 hours, normal growth 
media was removed and growth media supplemented with drug at the LD-10 value was 
added. Eight wells were used for each drug, providing a well for each time point per drug. 
Every 24 hours, media was removed and the cells were washed with 1X PBS before new 
LD-10 dosed media was added. Every 12 hours, cells treated with each drug were lysed 
using RIPA buffer and protein was collected. There were three biological replicates for 
each drug and time point. Time points were as follows: 12 hr, 24 hr, 36 hr, 48 hr, 60 hr, 72 
hr, 84 hr, 96 hr.  
 
Enzyme-Linked Immuno Sorbent Assays (ELISAs) 
The concentration of protein from cells treated with each drug at each time point 
was measured using a Bicinchoninic acid (BCA) kit (Pierce). Pre-coated 96-well ELISAs 
(Life Technologies) were used to measure the S396 (a form of p-tau found in higher 
concentrations in AD patients) and total tau concentration for each sample. 25000 pg/ul of 
protein was used for each well in the ELISA, and samples were run in triplicate.   
 
Validation in H4-tau cells 
The two drugs that had the most significant impact on the p-tau to total tau ratio 
(Fasudil and T343) were tested again to validate the results. In addition, two drugs that did 
not affect the p-tau to total tau ratio were re-tested. Y27632 was of interest due to previous 
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research stating that treatment using the drug decreased learning and memory in sham 
animals, which was contradictory to our previous results. T299 was of interest because it 
had a similar ROCK inhibition profile with T343, yet produced different results. 
Three changes were made in the protocol. First, 4 biological replicates were used 
per drug treatment time point. Second, two time points were added previous to the 12-hour 
time point: 0 hours and 6 hours. Finally, the drugs were applied at their LD-50 dosages to 
ensure that the two negative drugs did not have an unnoticeable effect at the LD-10 dosage.  
 
RNA collection and sequencing 
The four drugs of interest selected during the protein stage (Fasudil, T343, Y27632, 
and T299) were used to treat H4-tau cells over a 36-hour time course at their LD-50 dosages. 
RNA was collected to be sequenced at the following time point: 0 hr, 3, hr, 6 hr, 12 hr, 24 
hr, 36 hr. RNA was collected using Trizol and eluted to 20ul using RNAse free water. 
Concentrations of RNA were determined using Ribogreen (Invitrogen), and quality was 
assessed using 2100 Bioanalyzer (Agilent Technologies). The TruSeq RNA Sample 
Preparation Kit (Illumina Inc) was used to prepare samples for sequencing, and the final 
libraries were validated on the 2100 Bioanalyzer and quantified using qPCR (7900HT, 
Applied Biosystems). Libraries were sequenced by 100bp paired-end sequencing on a 
HiSeq2000 (Illumina Inc).  
 
Calculation 
To analyze results from ELISAs, two-way ANOVAs with factors 1) drug vs vehicle 
and 2) time, were used to determine significance for each drug across the time course. 
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Pairwise t-tests were performed in order to determine which of the drug treatments caused 
a significantly different p-tau to total tau ratio in comparison to vehicle treatment. 
 Analysis of RNA results were completed as follows: Illumina BCL files were 
converted and demultiplexed (bcl2fastq 2.170. Fastq files were trimmed of adapter 
sequences (Cutadapt 1.8.3) and aligned to the human reference genome GRCh37 (STAR 
2.5.0). Sequencing and RNA quality control reports were generated (FastQC 0.11.4 and 
Qualimap 2.1.3). Aligned reads were summarized as gene counts (featureCounts 1.4.4). 
Pairwise differential expression was conducted between groups with the R package 
DESeq2 (v1.10.1). 
 
Results 
Enzymatic Activity 
The enzymatic activity for Fasudil, Y27632, T343, and T299 are available in Table 
1. Each number is the IC-50 value, or the amount of drug necessary to decrease ROCK I 
or ROCK II to 50% of the original amount.  
 
Protein 
ELISA results from protein collected from the cells were analyzed using a two-way 
ANOVA, for the ratio of ptau to total tau with variables of treatment and time. Treatment, 
time, and the interaction of treatment and time were found to be significant (p = 2.2 x 10-
16, 1.8 x 10-8, and 0.0014 respectively).  
Of the 13 tested drugs, Fasudil (p = 0.0003; Fig. 4), T303 (p = 0.02), and T343 (p 
= 0.01; Fig. 6) were the only drugs that displayed a significant change in the p-tau to total 
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tau ratio (Fig. 1-3) using pairwise t-test. These drugs caused a significant decrease in the 
ratio. Surprisingly, Y27632 showed no significant difference across the time course (p=0.8) 
(Fig. 5). T299, a drug that has similar enzymatic activity levels for both ROCK I and II 
when compared to T343, also surprisingly showed no significant difference across the time 
course (p= 0.9) (Fig. 7).  
ELISA results from H4-tau cells treated by either Fasudil, Y27632, T299, or T343 
at the LD-50 were analyzed using a two-way ANOVA, for the ratio of p-tau to total tau 
with variables of treatment and time. Treatment, time, and interaction of treatment and time 
were found to be significant (p = 5.3 x 10-12, 9.6 x 10-6, and 0.04 respectively). Pairwise t-
test showed that the results were similar to the LD-10 dosage for Fasudil and T343, but not 
for Y27632 nor T299. Figure 9 shows that Y27632 decreased the p-tau to total tau ratio (p 
= 0.0009) and T299 increased the ratio (p = 1.9 x 10-7). Both Fasudil and T343 were 
validated as “positive” drugs that decreased the p-tau to total tau ratio in the cells. Fasudil 
was found to significantly decrease the p-tau to total tau ratio (p = 0.001), as was T343 (p 
= 1.2 x 10-7).  
 
RNA 
At every point of the RNA time course, Fasudil showed a significant decrease in 
MAPT expression (Figure 10). None of the other three drugs tested for changes in RNA 
expression showed such robust effects; however, there were additional expression changes 
that lasted through several time points (Table 2). For example, Fasudil showed a significant 
decrease in expression of SOX6 at timepoints 6 hours through 36 hours, and T299 showed 
a significant decrease in expression of ILII and ESM1 at timepoints 6 hours through 36 
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hours. It is also important to note that T343 showed a significant decrease in expression of 
GDA, which has been considered to play an important role in microtubule stabilization. 
All significant results for each drug treatment can be found in Table 4c. 
 
Discussion 
ROCK inhibitors did not produce the same effect on the ratio of p-tau to total tau 
in H4-tau cells. While a lack of significant difference in the p-tau to total tau ratio in cells 
treated by drugs at the LD-10 dosage was expected, as well as differences in effect size 
between different drug treatments, an opposite treatment effect with the treatment of T299 
at the LD-50 dosage was unexpected.  
Examining the IC-50, or the concentration of the drug at which the kinase response 
is reduced by half, all four of the drugs tested at the LD-50 dosage are similarly effective 
in inhibiting ROCK II. Fasudil is the least effective, with an IC-50 of 1.9uM, and T343 is 
the most effective with an IC-50 of 0.013uM. T299 and Y27632 have similar IC-50 for 
ROCK II, at 0.6uM and 0.3uM respectively. It is interesting that both Fasudil and T343 
significantly decrease the p-tau to total tau ratio at the lower dosage of LD-10, even though 
Fasudil has the highest IC-50, indicating that it is the least efficient at inhibiting ROCK II. 
This cannot be explained by the IC-50 for inhibition of ROCK I, as Fasudil is again the 
least efficient of the four in inhibiting ROCK I at 10.7um. The other three drugs inhibit 
ROCK I with an IC-50 below 1uM. Finally, Y27632 seemed to have a dose-dependent 
molecular effect on the ratio of p-tau to total tau, with a trend toward an increased ratio 
with a low dose of LD-10, and a significantly decreased ratio with a high dose of LD-50. 
Along with the surprising increase of ratio with treatment by T299, these dose-dependent 
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differences beg the question of what mechanistically is occurring, possibly outside of the 
ROCK pathway, to cause these differences.  
Next Generation Sequencing was performed on RNA from treated cells to 
determine which genes are controlled by the downstream targets of the ROCK inhibitors. 
We predicted that ROCK inhibition would create differences in gene expression in those 
genes, which may be related to the proteins that are known to be affected—i.e., MLC 
phosphatase, LIMK, PTEN, Akt, and cofilin. Results from Next Generation Sequencing 
also yielded interesting results, in that there were no transcriptional changes that were 
similar between Fasudil and T343, the two drugs that had caused the largest decrease in 
the p-tau to total tau ratio. This could indicate that the two drugs, while ROCK inhibitors 
with the same effect on p-tau, are not working through the ROCK pathway in order to 
produce those results. Due to the result showing that MAPT expression levels are 
significantly decreased over the entire time course when Fasudil is applied, it is highly 
likely that the change in phosphorylated tau is due to the changes in MAPT. Another gene 
expression change that is relevant to microtubules was GDA. GDA is a gene that has been 
associated with microtubule assembly, but has not been associated with AD. Application 
of T343 significantly decreased GDA across time points 3, 6, and 12. GDA could be the 
mechanism of action for changes in tau phosphorylation in cells treated by T343. 
One approach that could better our understanding of the mechanisms through which 
these drugs are acting on the p-tau to total tau ratio is to perform kinase assays for proteins 
that are known to be involved in the phosphorylation of tau. This could provide information 
on the non-RNA molecular mechanisms through which each of the drugs is affecting, or 
not affecting, the ratio of p-tau to total tau. A more elegant, but costly, method would be to 
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use a mass proteomics approach, to determine whether there are changes in proteins outside 
of what we would expect as well.  
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CHAPTER 3 
THE EFFECT OF ROCK INHIBITORS ON ALZHEIMER'S DISEASE: AN IN VIVO 
STUDY 
Abstract 
ROCK is an enzyme that plays a key role in neuronal cells. ROCK inhibitors Fasudil and 
Y27632 have been shown to increase learning and working memory in aged rats and rats 
with concussion-induced brain injury, respectively. Conversely, Y27632 has been shown 
to decrease learning and working memory in normal rats, exhibiting no pathology. 
Previous work with thirteen different ROCK inhibitors applied to human neuroglioma 
cells overexpressing 4-repeat tau (H4-tau) cells has shown that Fasudil and Y27632 
decreases the ratio of phosphorylated tau to total tau in comparison to cells treated with 
vehicle. T343, a novel ROCK inhibitor, also decreased the ratio, while T299, another 
novel ROCK inhibitor with similar enzymatic inhibition, increased the ratio. With both 
behavioral and molecular data showing that ROCK inhibition has the potential for 
improving the outcome of Alzheimer’s disease patients, we tested these drugs on triple-
transgenic Alzheimer’s disease mice. Fasudil, Y27632, T343, and T299 were tested on 
adolescent mice for sixty days to first determine whether the drugs, when mice are treated 
orally via drinking-water, would cross the blood-brain barrier and be present in the brain. 
All drugs but T299 conclusively reached the brain; however, only Fasudil and Y27632 
were tested on a larger group of mice. T299 and T343 were intended to be used in a 
comparative study, and therefore, neither was used. The second group of mice tested 
were treated for 12 months beginning at 3 months of age, and tested on a series of 
learning and memory tests: the radial arm water maze, Morris water maze, and fear 
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conditioning test at 10, 12, and 15 months respectively. Fasudil treatment in wild-type 
mice showed a marked improvement in spatial reference memory at 10 months and fear 
memory at 15 months, while Y27632 treatment in AD mice showed a significant 
impairment in spatial reference memory at 10 months. Brains were dissected and tested 
for markers of Alzheimer’s disease. Fasudil-treated mice showed decreases in Aß and in 
phosphorylated tau. Y27632-treated mice showed an increase in phosphorylated tau and 
Aβ. Thus, Fasudil continues to be a drug of interest in the treatment of Alzheimer’s 
disease. 
 
Experimental Procedures 
Mice 
The triple transgenic Alzheimer’s disease (3xTg-AD) mice were generated as 
previously described (Oddo et al., 2003). Only female mice were used, as the 
neuropathologic variability in females is small relative to males. All mice were housed 4–
5 per cage, kept on 12 hours light/dark cycle and given ad libitum access to food and 
water. Animal care and treatments were in accordance with the applicable regulations of 
the vivarium (The Institutional Animal Care and Use Committee of the Banner Sun 
Health Research Institute; The Institutional Animal Care and Use Committee of Arizona 
State Univeristy). 3xTg-AD mice were used along with C57BL6/129S mice (wild-type). 
In the pilot study, a total of 30 3xTg-AD mice were used. During the final study, a total 
of 43 3xTg-AD mice and 45 wild-type mice were used. For the course of the entire study, 
a total of 74 3xTg-AD mice and 45 wild-type mice were used. 
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During the pilot study, commercially available ROCK inhibitors Fasudil and 
Y27632 were used along with 2 novel ROCK inhibitors developed at TGEN—T343 and 
T299. However, for the final study, only Fasudil and Y27632 were used. 
 
Pilot 
3xTg-AD mice were treated with Fasudil, Y27632, T343, T299 or vehicle 
(25mg/L sucrose) through drinking water over the course of 60 days. Drinking water was 
freely provided and replaced twice weekly and in the case of empty bottles between 
bottle replacements. Drugs were added to the water at two dosages: 30mg/kg and 
100mg/kg.  
Water intake was monitored over the course of 60 days to ensure consumption 
levels and overall health in the mice. Mice were sacrificed after 60 days, and brain tissue 
was collected to test drug blood brain barrier crossing. The hippocampus was removed 
and fresh frozen, and prepared for HP-LC. Results from HP-LC were not completed in 
time for the start of the main study —however Fasudil and Y27632 have previously been 
shown to reach the brain in rodents at 30mg/kg; therefore these two drugs were used for 
the remainder of this study. 
 
Treatment 
3xTg-AD mice and wild-type mice were continuously treated with 30mg/kg 
Fasudil, Y27632, or vehicle (25mg/L sucrose) through drinking water starting at 3 
months of age until 15 months of age. Mice were weighed weekly to ensure that 
treatment dosage remained accurate over time.  
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Behavior 
Mice were tested on memory at three separate times, using three different 
memory tests. Mice were tested at 10, 12 and 15 months of age on the radial arm water 
maze, Morris water maze, and contextual fear conditioning test respectively. 
 
Radial Arm Water Maze 
The radial arm water maze, which tests spatial reference memory (Alamed et al 
2006) was conducted at 10 months of age. The radial arm water maze apparatus consisted 
of eight identical arms, each with a slot for holding a clear plastic escape platform at the 
end. Each mouse had a randomly designated goal arm with the platform. On the first day, 
a flag was placed at the top of the platform during the first trial, and every other trial 
thereafter. Mice were randomly placed in each of the seven non-goal arms to start each 
trial. Extramaze cues are used by the mice to find the goal arm. Mice were given 60 sec 
to find the platform, with errors being considered as a full body entry into an incorrect 
arm. After 60 sec, if the mouse did not find the platform on its own, it was gently moved 
to the platform by the experimenter. Once on the platform, a 10 sec acclimation period to 
the location was given, followed by the placement in a heated cage for 20 sec. After six 
successive trials, mice were returned to their home cage until all experimental animals 
underwent their first set of six trials. Then, each mouse received another set of six 
successive trials. The flag was placed at the end of the goal arm during every other trial 
for the second set of trials as well. After each mouse received their second set of trials, 
the mice underwent a final set of three trials. The flag was not placed in the goal arm 
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during the third set of trials. On the second day, the mice underwent two sets of six trials 
and then a set of three trials, the same as the first day. However, on the second day, the 
flag was not placed in the goal arm at all.  
 
Morris Water Maze 
The Morris water maze consists of a circular plastic tank of 1.5 m in diameter 
filled with water and kept at 25°C. A platform (14 cm diameter) was placed 1.5 cm under 
the surface of the water and made invisible to mice by adding white nontoxic paint to the 
water. The water was maintained at 25°C throughout the duration of the testing. The tank 
was in a room with several extramaze visual cues, which served as reference points for 
mice. The location of the cues and platform were kept constant throughout the testing 
period. Mice were trained to find the hidden platform for 5 consecutive days, four 
training trials per day. Before the first trial of the first day, mice were placed on the 
platform for 10 seconds, after which they were placed in the water until they reached the 
platform for a maximum of 60 seconds. When a mouse found the platform, it was placed 
in a warm holding cage for 25 seconds before starting the next trial. If a mouse failed to 
find the platform in 60 seconds, it was gently guided to the platform location by the 
experimenter and allowed to stay on it for 10 seconds after which it was placed in the 
warm holding cage. Extreme care was taken to minimize animal stress during these 
procedures. Spatial memory was assessed during a probe trial, conducted 24 hours after 
the last training trial. During the probe trials, the platform was removed from the water 
and mice freely swam in the tank for 60 seconds. The entire test was recorded with a 
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video camera that was mounted on the ceiling. Data were obtained using specialized 
tracking software (Noldus Information Technology, Leesburg, VA, USA). 
 
Fear Conditioning 
The contextual fear conditioning (CFC) test was performed using an apparatus 
from San Diego Instruments. On day 1, mice were placed in the conditioning chamber 
and allowed to freely explore for 210 seconds, at which point, a foot shock was 
administered (0.3 mA, 2 s). After the shock, mice remained in the chamber for an 
additional 30 seconds. On day 2 (24 h after training), mice were placed back in the 
chamber for 4 minutes. Freezing, defined as the complete lack of motion, except 
breathing, for a minimum of 2 seconds, was recorded and analyzed by Freeze Monitor 
software (San Diego Instruments). The percent of freezing during each testing trial was 
reported. 
 
Sacrifice 
After the contextual fear conditioning test was performed, mice were sacrificed. 
Mice were sedated by CO2. Mice underwent cervical dislocation and heads were 
removed using scissors. The brain was removed and sliced sagittaly. Half of the brain 
was placed into 4% paraformaldehyde (PFA) for 48 hours. PFA was replaced using PBS 
with 0.02% sodium axide, to be used for histology. The hippocampus was removed from 
the other half of the brain and placed on dry ice to fresh freeze the tissue. The 
hippocampus was lysed and protein extraction was used to perform western blots and 
ELISAs.  
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Molecular 
Protein extraction 
Mice were sacrificed by CO2 asphyxiation, their brains removed and sagittally 
bisected. Half of the brain was drop-fixed in 4% paraformaldehyde and used for 
histological and immunohistochemical experiments. The hemibrain or different brain 
areas, such as hippocampus and cortex, were collected and stored at -80°C until use. 
Frozen brain areas (hemibrain without cerebellum, hippocampus or cortex) were 
processed as described previously (Caccamo et al., 2013). Briefly, brains were 
homogenized in a solution of tissue protein extraction reagent (T-PER, Pierce) containing 
0.7 mg/mL of pepstatin A supplemented with a complete mini protease inhibitor tablet 
(Roche Applied Science) and phosphatase inhibitors (Invitrogen). The homogenized 
mixtures were centrifuged at 4°C for 1 hour at 100,000 g, and the resulting supernatant 
was stored as the soluble fraction. The pellet was re-homogenized in 70% formic acid 
and centrifuged as described above. The supernatant was stored as the insoluble fraction. 
 
Western Blot 
Proteins from the soluble fraction were resolved by 10% or 4-12% BisTris SDS 
polyacrylamide gel electrophoresis (Life Technologies) under reducing conditions and 
transferred to a nitrocellulose membrane. Membranes were developed as described 
previously (Orr et al., 2014). Briefly, membranes were incubated for 1 hour in 5% nonfat 
milk in TBST (0.1% Tween 20, 100 mM Tris, pH 7.5; 150 mM NaCl) and then incubated 
overnight in primary antibody. 
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The blots were rinsed in TBST for 30 minutes and then incubated in goat anti-
mouse IRDye 680LT or goat anti-rabbit IRDye 800CW LI-COR secondary antibodies 
(1:10000) for 1 hour at room temperature. The membranes were rinsed for 30 minutes in 
TBST, imaged, and analyzed using the Odyssey (LI-COR, Lincoln, NE, USA). The 
protein levels reported were obtained as a ratio between the band intensity of the protein 
of interest and the band intensity of β-actin or GAPDH, used as loading control. 
 
Western Blot Antibodies 
 Actin was used as a loading control. Western blots were used to measure levels of 
total tau, tau phosphorylated at Ser 202, full length APP, and the APP c terminal. The 
antibodies used to measure these levels were HT7 (Thermo Fischer), CP13 (Cell 
Signaling), 6E10 (BioLegend), and CT20 (Millipore) respectively.  
 
Immunohistochemistry 
Hemibrains were drop fixed in 4% paraformaldehyde in phosphate-buffered 
saline for 48 hours and then transferred into 0.02% sodium azide in phosphate-buffered 
saline until slicing; 50-μm-thick free-floating sections were subsequently obtained using 
a vibratome. 
Sections were washed twice with TBS (100 mM Tris pH 7.5, 150 mM NaCl), 5 
minutes each, followed by a 30-minute incubation in 3% H2O2 to quench endogenous 
peroxidase activity. Next, sections were transferred into TBS-A (100 mM Tris pH 7.5, 
150 mM NaCl, 0.1% Triton X-100) and TBS-B (100 mM Tris pH 7.5, 150 mM NaCl, 
0.1% Triton X-100, 2% bovine serum albumin) for 15 and 30 minutes, respectively, to 
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block nonspecific binding. Finally, the proper primary antibody was applied overnight at 
4°C; antibody dilution was made in TBS-B. 
Sections were washed 3 times in TBS in order to remove excess antibody, and 
incubated in the suitable secondary antibody for 1 hour at 25°C. Signal was enhanced by 
incubating sections in the avidin-biotin complex (Thermo Scientific) for 1 hour at 25°C. 
Sections were then washed and developed with diaminobenzidine substrate using the 
avidin– biotinhorseradish peroxidase system (Vector Labs). Images were obtained with a 
digital Zeiss camera and analyzed with ImageJ software. Quantification of staining was 
achieved using pixilation detection acquired by ImageJ. A threshold was set using a 
positive control and a standard mean gray area function, which allowed the set software 
to recognize positive staining and decrease error caused by background staining. Abeta42 
(Millipore) was used to visualize Aß42. AT8 (Fisher) used to visualize tau phosphorylated 
at Thr205/Ser202. 
 
Enzyme-linked immunosorbent assay 
ELISAs were performed using Invitrogen’s prepared Aß40 and Aß42 plates. 
ELISAs were performed on both soluble and insoluble fractions of protein extracted from 
the hippocampus.  
 
Statistical Analyses 
All data were analyzed using R. Data were analyzed using one- or two-way 
ANOVA followed by Bonferroni’s post hoc analysis or Dunnet’s multiple comparison 
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tests when applicable. Selective experiments were analyzed using Student’s t-test, as 
specified in the results section.  
 
Results 
Pilot 
Over the course of 60 days, none of the treated mice suffered adverse effects, 
other than weight loss in the Y27632 treated mice. These mice were not drinking the 
treated water in the beginning of the study. After sucrose was added to each treatment 
including Y27632, the mice began drinking the treated water, and regained weight and 
health. While the Y27632-treated mice did not receive the same amount of drug during 
the beginning of the pilot, this was resolved by the time the main study began with a new 
set of mice. All groups of mice drank similar amounts of water after the sucrose was 
added. No mice died before the end of the 60 days. 
 
Behavior: Radial arm water maze 
Total Errors 
Fasudil-treated wild-type mice committed fewer total errors than vehicle-treated 
mice (p = 0.01) on Day 2 (Figure 12). Fasudil-treated 3xTg-AD mice did not have a 
significantly different number of total errors than vehicle-treated mice (p = 0.22) on Day 
2 (Figure 11). Y27632-treated wild-type mice did not have a significantly different 
number of total errors than vehicle-treated mice (p = 0.35) on Day 2 (Figure 14). 
Y27632-treated 3xTg-AD mice committed more total errors than vehicle treated mice (p 
= 0.016) on Day 2 (Figure 13).  
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Pairwise t-test were used to determine whether there were significant differences 
between treatment groups during each individual trial—the only significant differences 
were found between Y27632-treated and vehicle-treated 3xTg-AD mice during trials 18 
(p = 0.00045) and 29 (p = 0.0028).  
There were no significant differences between groups on Trial 16, which 
measures overnight retention (Figure 19). 
 
Re-entries 
The number of re-entries into incorrect arms was not significantly different 
between any drug-treated and vehicle-treated groups on Day 2 (Figures 14-17). However, 
pairwise t-test was used to determine whether there were significant differences between 
groups at each individual trial, and some differences were found. Fasudil-treated 3xTg-
AD mice had significantly fewer re-entries during trial 21 (p = 0.0042) in comparison to 
vehicle-treated mice, and Y27632-treated 3xTg-AD mice had significantly more re-
entries during trials 18 (p = 0.00014), 23 (p = 0.026), and 29 (p = 0.022). 
 
Time 
Across all points, 3xTg-AD mice treated with Y27632 took significantly longer 
than vehicle-treated 3xTg-AD mice (p=0.012) to reach the platform. Fasudil treated 
3xTg-AD mice did not take a significantly different amount of time to reach the platform 
in comparison to vehicle-treated mice (p=0.53). Fasudil treated wild-type mice performed 
significantly better than vehicle-treated wild-type mice (p<0.001). Y27632-treated wild-
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type mice did not perform significantly differently in comparison to vehicle-treated mice 
(p=0.59). 
On the first trial of the second day, 3xTg-AD mice treated with Y27632 
performed significantly worse than untreated wild-type (p=0.02). While the untreated 
3xTg-AD mice were not significantly different from the untreated wild-type mice, this 
shows that the Y27632 treatment decreased performance further than pathology alone. 
 
Behavior: Morris Water maze 
 On Days 1 and 2, there were no significant differences in distance swam on the 
MWM between treatment groups. On Day 3, Fasudil-treated 3xTg-AD mice trended 
toward a decreased distance swam (p = 0.069) and Y27632-treated 3xTg-AD mice had a 
significantly decreased distance swam (p = 0.04) in comparison to vehicle-treated mice 
(Figure 20). On day 4, Y27632-treated wild-type mice swam a significantly shorter 
distance than vehicle-treated mice (p = 0.005, Figure 21).  
Probe trial 
The number of times the Fasudil-treated 3xTg-AD mice (M = 1.75) entered the 
platform area was not significantly different from vehicle-treated mice (M = 1.1; t = 
1.017, df = 19.678, p = 0.3). The number of times Y27632-treated 3xTg-AD mice (M = 
1) entered the platform area was not significantly different from vehicle-treated mice (t = 
-0.187, df = 15.265, p = 0.9). The number of times Fasudil-treated wild-type mice (M = 
2.1) entered the platform area was not significantly different compared to vehicle-treated 
mice (M = 3.8; t = 2.055, df = 19.052, p = 0.054). The number of times Y27632-treated 
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wild-type mice (M = 3.5) entered the platform area was not significantly different from 
untreated wild-type mice (t = 0.279, df = 26.799, p = 0.8) (Figure 24). 
The amount of time, within the 60 second timeframe allotted to each mouse, that 
each mouse spent in each of the quadrants was also measured. The time spent in the 
quadrant the platform was previously located, as well as the time spent in the quadrant 
opposite the platform quadrant, was analyzed. Neither the Fasudil-treated nor Y27632-
treated 3xTg-AD mice spent a significantly different amount of time in the platform 
quadrant nor in the opposite quadrant, in comparison to the vehicle-treated 3xTg-AD 
mice (Figure 25, 27). The same null results between drug-treated and vehicle-treated 
mice were found in the wild-type mice (Figure 26, 27).  
 
Overnight retention 
 There was no significant difference in the distance swam on the final trial of each 
day in comparison to the distance swam on the first trial of the next day (i.e. the final trial 
of Day 2 in comparison to the first trial of Day 3), for any treatment group for either 
3xTg-AD mice (Figure 22) or wild-type mice (Figure 23).  
 
Behavior: Fear Conditioning 
 Fasudil-treated 3xTg-AD mice showed significantly increased freezing levels 
when compared to vehicle-treated 3xTg-AD mice (t(393.82)  = 3.23, p = 0.0013) and 
vehicle-treated wild-type mice (t(441.07) = 3.23, p = 0.02) on the second day (Figure 28, 
29). Y27632-treated and vehicle-treated 3xTg-AD mice did not have a significantly 
different freeze duration (t(172.52) = 0.41, p = 0.68) on the second day (Figure 30, 31).  
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Western Blot 
The antibody 6E10 was used to measure total APP. The expression of 6E10 was 
significantly decreased in Fasudil treated mice compared to vehicle treated animals 
(t(5.35) = 4.63, p = 0.0048). 6E10 expression was not significantly different in Y27632 
treated mice in comparison to vehicle treated mice (Figure 37). CP13 was used to 
measure tau phosphorylated at Ser202, one of the abnormal phosphorylation sites for AD 
patients. HT7 was used to measure total tau. CT20 was used to measure APP C-terminal 
fragments. CT20 (Figure 38), CP13 (Figure 40), and HT7 (Figure 39) expression was not 
changed in either Fasudil- nor Y27632- treated groups in comparison to vehicle-treated 
mice. All samples showed similar actin expression levels.  
Further analysis was necessary for the ratio of ptau to total tau. The ratio of CP13 
expression and HT7 expression was used to determine the ratio of ptau to total tau in the 
3xTg-AD mice. Fasudil treatment elicited no changes in the ratio; however Y27632-
treated mice had a significantly higher ratio than vehicle-treated mice (t(6.0774) = -
2.4837, p = 0.047) (Figure 41).  
 
ELISA 
Treatment with Fasudil in the 3xTg-AD mice showed a significant decrease in 
Aß-40 in both soluble (t(45.5) = 2.3, p = 0.03) (Figure 44) and non-soluble (t(40.91) = 
2.8, p = 0.008) (Figure 42) layers compared to vehicle treatment. Aß-42 levels were not 
significant different in either layer (Figure 43, 45). Treatment with Y27632 in the 3xTg-
AD mice did not have a significant effect on Aß-40 in either layer, or Aß-42 in the non-
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soluble layer. However, in the soluble layer, Y27632 treatment significantly increased the 
level of Aß-42 (t(42.1) = -3, p = 0.005). 
 
Immunohistochemistry 
In the hippocampus, Fasudil-treated mice (M = 65700.36) did not have 
significantly different levels of Aβ42 staining in comparison to vehicle-treated mice (M = 
82259.94), although there was a trend toward decreased staining (p = 0.055). Y27632-
treated mice (M = 70657.13) did not have significantly different levels of Aβ42 (Figure 
46). In the cortex, neither drug treatment (Fasudil M = 48387.68; Y27632 M = 35736.6) 
produced a significantly different level of Aβ42 in comparison to vehicle treatment (M = 
45953.82; Fasudil: t = -0.202, df = 9.245, p = 0.844; Y27632: t = 1.254, df = 7.505, p = 
0.247) (Figure 48).   
Fasudil-treated mice (M = 14673.07) had significantly decreased AT8 staining 
than vehicle-treated mice (M = 23187.98; t = 4.354, df = 4.758, p = 0.0082). Y27632-
treated mice (M=21400.11) and vehicle-treated mice did not have a significantly different 
amount of AT8 staining (t = 0.778, df = 5.552, p = 0.4683) (Figure 50). 
 
Discussion 
In the radial arm water maze, the number of errors is indicative of working 
memory, while the amount of time to reach the platform is indicative of reference 
memory. Working memory and reference memory are two of many types of memory 
affected in AD. Working memory is the mental processing system that is used to hold and 
manipulate transitory information to guide behavior. In the radial arm water maze, after a 
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mouse makes an error, working memory would be used to avoid making that error again. 
The total number of errors is used to measure working memory. If a mouse continually 
makes the same errors, it is likely that the mouse is not holding and manipulating the 
information about the location of the platform. Our findings show that neither of the 
treatments made a significant difference in the number of re-entries into incorrect arms, 
for either 3xTg-AD nor wild-type mice in comparison to their respective vehicle-treated 
controls. This indicates that working memory is not affected by Fasudil or Y27632 
treatment at 10 months of age at this dosage.  
Reference memory is learned knowledge that can be used throughout the 
behavioral task, and is correlative to human semantic memory. Semantic memory is a 
type of long-term memory that is considered common knowledge. While the location of 
the platform is not considered common knowledge, reference memory is as similar as we 
are able to measure in mice. The time that the mouse takes to reach the platform is 
measured to analyze reference memory because if a mouse remembers that the platform 
is in the direction of a specific extra maze cue, the mouse has consolidated the 
information from prior trials. The ability to remember this information should decrease 
the amount of time that it takes the mouse to reach the platform. Our findings indicate 
that Fasudil treatment in wild-type, but not 3xTg-AD mice, improves reference memory 
at 10 months of age at this dosage. However, Y27632 treatment in 3xTg-AD, but not 
wild-type mice, impairs reference memory at 10 months of age at this dosage. 
Y27632 also caused 3xTg-AD mice to perform worse on reference memory in 
overnight retention trials. Overnight retention is a better indicator of long-term memory 
due to the longer period of time between trials. Y27632-treated mice may be utilizing 
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working memory to reach the platform at a faster time in subsequent trials during the 
second day. 
The Morris water maze tests for reference memory as well. The Morris water 
maze was used in order to create a battery of tests to better understand the effects of the 
drugs on memory, and because the Morris water maze is a classic task used to test 
memory in AD rodent models. There was a lack of significant results, both for Fasudil-
treated and Y27632-treated mice in comparison to vehicle-treated mice, in both the AD 
model as well as the wild-type mice. These results suggest that neither treatment had an 
effect on memory at 12 months of age and with the dosage used. However, as we did see 
an effect on spatial reference memory at 10 months of age with the use of the radial arm 
maze, it is possible that the lack of effect is due to practice effects, or due to a difference 
in sensitivity between the tasks. Also, only on Day 3, Y27632 treatment in 3xTg-AD 
mice decreased overall swim distance significantly, and Fasudil treatment in 3xTg-AD 
mice showed a trend toward decreased swim distance. While these results are not seen on 
other days, it is possible that treatment could have an effect with higher dosage, or that a 
task with a higher sensitivity to different effects would have shown a significant 
improvement. Finally, if mice were not previously tested on spatial reference memory, it 
is possible that a lack of practice effect may have produced significant results at 12 
months of age. Future work could include groups that are tested only on at one of the 
three time points, in order to minimize these effects, and could use the same task for each 
of the groups, and therefore each time point.  
Overnight retention in the Morris water maze task was measured by comparing 
the final trial of one day to the first trial of the next day, for each day. There were no 
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significant differences in vehicle-treated 3xTg-AD mice, indicating that we were not able 
to show that overnight retention was impaired. Therefore, while neither Fasudil nor 
Y27632 treatment in 3xTg-AD mice led to an impairment in overnight retention, we are 
unable to determine whether this was due to the drug or due to an issue with the 
behavioral task. However, while there was no significant difference between both 
Fasudil- or Y27632-treated and vehicle-treated 3xTg-AD mice in time spent in the 
platform area during the probe trial, there seems to be a trend toward increased time in 
the platform area in comparison to the vehicle-treated mice, signifying that both 
treatments may be improving reference memory slightly.  
Western blot results for Fasudil-treated mice show no difference in the expression 
of p-tau, or the ratio of p-tau to total tau. Meanwhile, immunohistochemistry results show 
a significant decrease in the expression of p-tau. This is likely due to differences in 
antibody—the western blot antibody measured tau phosphorylated at Ser202, while the 
immunohistochemistry antibody measured tau phosphorylated at both Ser202 and 
Thr205. Different antibodies were used due to their efficiency in the particular molecular 
tests they were used for. Y27632 treatment resulted in an increase in p-tau, as seen in the 
western blot, but not with immunohistochemistry. Thus, it seems that Fasudil and 
Y27632 treatment may decrease tau phosphorylation at Thr205, as Y27632’s effect on 
Ser202 was muted. Increased phosphorylation at both sites are associated with an 
increase in abnormal tau processing and paired helical filaments, in the pathogenesis of 
AD as well as in other tauopathies. 
 While no memory tasks were conducted at 4 months of age, the first point of 
significant cognitive deficits, it would have been informative to do so, and should be 
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tested in the future. The improvements seen in fear memory in the 3xTg-AD mice may 
have been due to a shift in decreased cognition, rather than in an overall improvement in 
cognition. The treatment with Fasudil may have slowed down the progression of the 
disease, rather than halting it, as we did not see improvements in spatial memory at 10 or 
12 months of age. Improvements in pathology were also noted in both tau 
phosphorylation and levels of Aβ40; however, this could also be due to a shift in AD 
pathology. Future work could further parse this out by adding sacrifice time points at 9 
months of age (significant amyloid pathology) and 12 months of age (significant early tau 
pathology). 
In conjunction with the results from the in vitro study, the results indicate that 
Fasudil decreases phosphorylation of tau. Y27632 treatment in vitro is also consistent 
with the results produced in vivo. While in vitro results for a high dosage of Y27632 
resulted in a decrease in the ratio of p-tau to total tau, a low dosage resulted in no 
significant difference, but with a trend toward an increased ratio. Thus, we hypothesized 
that there may be a dose-dependent difference in the molecular mechanisms of the drug, 
and its effect on p-tau. The dosage used for the in vivo study was on the low end of the 
dosages previously used in mice receiving drug orally. It is possible that the same 
mechanisms that caused a trend toward increased p-tau to total tau ratio in vitro also 
caused a significant increase in the p-tau to total tau ratio in vivo. 
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CHAPTER 4 
CONCLUDING REMARKS 
AD is the most common subset of dementia, affecting an estimated 5.4 million 
Americans in 2015 (Gaugler et al., 2016). An estimated 236 billion dollars was spent on 
AD in 2016. Because patients in the final stages of AD are bedbound and incapable of 
caring for themselves, they require around-the-clock care, creating a large need for 
caregivers. This can mean high costs both financially and in time spent away from work 
for family members of those with AD. While some risk factors, such as carrying the APOE-
e4 allele, have been identified, there have been no identifiable early biomarkers of the 
disease in non-familial AD. Further, no effective treatment options for AD are available, 
with the only therapeutics currently available alleviating symptoms for short periods with 
no effect on the pathology of the disease. It is critical to find early biomarkers and to 
develop a reliable and effective therapeutic to prevent and treat AD. This report identifies 
the current state of biomarker research as well as the potential for ROCK inhibitor Fasudil 
as an AD treatment that affects the neuropathology of AD.  
Our early results are particularly interesting due to previous studies that have shown 
conflicting outcomes in learning and memory through the use of different ROCK inhibitors. 
While Fasudil has been shown to improve learning and memory in aged rats, for example, 
Y27632 has been shown to lead to decreased scores on learning and memory tests in normal 
rats. However, Y27632 has also been shown to increase learning and memory in rats that 
have ischemia. Our study adds to complex understanding of how these drugs affect 
cognition and elucidates underlying molecular pathways in learning and memory. 
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While the H4-tau cells used for this study are convenient for studying the effect of 
drugs on p-tau and total tau levels due to elevated levels of tau protein, the cells do not 
molecularly or functionally express similarly to AD neurons. Not only do the cells lack an 
overexpression of Aβ, the tau phosphorylation can also be called into question. First, the 
cells overexpress 4-repeat tau, which is a non-physiological condition. Second, the 
overexpression of tau can create the possibility of a cytoplasmic pooling of tau not bound 
to microtubules. This could lead to normally protected phospho-epitopes becoming 
exposed and hyperphosphorylated. Further investigation is necessary, not only to 
determine the cause of the difference in ROCK inhibitor treatments on the p-tau to total 
tau ratio, but also to ensure that these differences and changes are seen in AD neurons as 
well. Future in vitro work will include molecular and morphology studies using cells more 
similar to AD neurons than H4-tau cells, such as primary neuronal cultures from 3xTg-AD 
mice.  
While others have studied the effects of Fasudil or Y27632 on tau or amyloid 
pathology, or learning and memory behavior, ours was the first to study two different 
ROCK inhibitors on an animal model, and to examine the drugs’ effects on both tau and 
amyloid pathology. This is the first study to create a comprehensive overview of the 
different effects of Fasudil and Y27632 in an AD mouse model. This study was also one 
of the first studies to test possible preventative therapeutics for AD with a chronic time 
course, beginning prior to both pathology and significant cognitive deficits, and continuing 
treatment and testing until old age. This study also used drinking water to treat mice orally, 
rather than through injections or other methods that may not be as accessible to patients 
with AD, if the treatment were to succeed. These methods are important, as acute high 
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dosage treatments injected into the bloodstream are not the treatment method that will 
likely be used for AD patients; yet many studies use this paradigm to test treatments in vivo.   
Non-steroidal anti-inflammatory drugs have been shown to decrease Aß, and it has 
been proposed that the pathway through which this occurs is the downregulation of the 
Rho-GTPase and downstream effectors, ROCK I and ROCK II. Application of ROCK 
inhibitor SR3677 in vitro has shown a marked decrease in Aß production and levels 
(Herskowitz et al., 2013). Fasudil treatment in rats injected with Aß42 improved learning 
and memory and reduced neuronal loss and injury (Song et al., 2013). The current study 
confirmed these findings—hippocampal tissue from Fasudil-treated mice had significantly 
decreased Aβ40 levels, as well as significantly reduced expression of APP, in comparison 
to vehicle-treated mice. 
Recent research has shown that ROCK I and ROCK II proteins are increased in AD 
patients as well as patients with mild cognitive impairments (Henderson et al., 2016; 
Herskowitz et al., 2013). However, our work also shows that there was no difference in the 
transcription of either ROCK I or ROCK II in AD patient samples in comparison to non-
AD samples (Figure 49). In conjunction, this supports the theory by Henderson et al., that 
the changes in ROCK protein levels are due to the increase in Aß oligomers. Depletion of 
ROCK I in vitro was found to decrease levels of APP, sAPP, and Aß40. ROCK I knock-
down mice were also found to have decreased levels of Aß40 (Henderson et al., 2016). 
However, other research shows an increase in Aß40 in vitro with the depletion of ROCK I 
(Herskowitz et al., 2013). Our research does not use full depletion of ROCK I or ROCK II, 
but does show a decrease in both Aß40 in the hippocampus in Fasudil-treated 3xTg-AD 
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mice, confirming the results of Henderson et. al, but also shows an increase in Aβ42 with 
Y27632 treatment.  
Our work in vitro showed a significant decrease in the ratio of p-tau to total tau 
using Fasudil. We hypothesized that this would translate to a decrease in p-tau and the p-
tau to total tau ratio in vivo in animals treated with Fasudil, as well as to an improvement 
in learning and memory results through behavioral testing. However, in our present study, 
while Fasudil significantly reduced tau phosphorylated at residues Ser202 and Thr205, 
Fasudil treatment did not significantly improve learning and memory on all behavioral 
tasks. Fasudil did, however, improve spatial references memory in wild-type mice, and 
improved contextual fear memory in both 3xTg-AD and wild-type mice. It is possible that 
an increased dosage would further improve cognition. 
Meanwhile, in vitro work showed that Y27632 decreased the p-tau to total tau ratio, 
but only with a higher dosage, and we hypothesized that this would translate to p-tau levels 
that were lower than vehicle-treated mice but higher than Fasudil-treated mice, and that 
there may be no change in learning and memory results. However, Y27632-treated mice 
exhibited a higher ratio of p-tau to total tau than vehicle-treated mice. The results from 
behavioral testing showed no changes in learning and memory, save for a worsening in the 
radial arm water maze at 10 months. These results could be due to the use of a low dosage 
of Y27632, which was shown to trend toward an increased p-tau to total tau ratio in vitro. 
A comprehensive summary of behavioral and molecular results for the in vivo study is 
available in Table 3.   
It is possible that the dosage of Fasudil in the present study was not strong enough 
to have a significant effect on learning and memory, but was strong enough to elicit changes 
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in tissue pathology, and to show a significant difference in learning only at the end-stages 
of the disease. Fear conditioning is also considered a very sensitive test, and may have been 
more capable of indicating an improvement than less sensitive tests. Further work should 
be considered to increase the dosage safely, to test whether Fasudil is able to decrease 
learning and memory issues in AD mice.  
This study attempted to discern whether Fasudil or Y27632 could be used as a 
preventative therapeutic, so the mice were treated beginning prior to the pathology onset. 
We are not able to determine whether the changes in tau pathology or total APP were due 
to consistent and early intervention, or due to the drug being administered at all. It would 
be interesting to test whether the same results can be obtained by treating mice with higher 
dosages after pathology onset, and for shorter duration. Further, in this study, drug was 
administered via drinking water. Since this study began, there have been improvements in 
technology of osmotic infusion pumps, such that the longest study using a pump has been 
7 months, with replacement every 4 weeks. Future work could use these infusion pumps to 
better regulate and control the amount of drug administered to mice, to ensure consistency 
in treatment. 
 Dosage is not the only variable that could have an effect on the cognitive and 
pathological outcome of treatment. Timing may also play a key role. While we began 
treatment at 3 months of age in order to treat preventatively, this may not have been early 
enough to use as a preventative therapeutic. 3xTg-AD mice have significant cognitive 
deficits beginning at 4 months of age. This means that there could already be some 
cognitive impairment prior to 4 months of age, even if it is not significant. If this is the 
case, our preventative treatment may be too late. In humans, dementia onset occurs two 
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decades after the first neuritic plaque; in 3xTg-AD, cognitive impairments precede 
pathology. Thus, it is difficult to time the treatment in such a way that mimics the treatment 
paradigm we aim for. However, beginning treatment earlier, such as 1 month of age, may 
allow us to begin treatment significantly prior to the onset of cognitive impairment.  
Here, we provide results from a preventative therapeutic paradigm, using two 
different ROCK inhibitors to treat 3xTg-AD mice and wild-type mice. Fasudil treatment 
resulted in significantly decreased amyloid and tau AD pathology, two hallmarks of the 
disease. Fasudil treatment also resulted in improved spatial reference memory at 10 months 
of age and contextual fear memory at 15 months of age in wild-type mice, and improved 
contextual fear memory in 3xTg-AD mice. Y27632 treatment, on the other hand, resulted 
in increased amyloid and tau AD pathology load, along with spatial reference memory 
impairment at 10 months of age in 3xTg-AD mice. While results from Fasudil treatment 
are promising, some changes in dosage and timing, along with future research on other 
ROCK inhibitors, will further provide clarity regarding the mechanisms through which 
these drugs may work to prevent and treat AD.  
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Drug Structure Molecular 
weight 
ROCK I IC-
50 (uM) 
ROCK II IC-
50 (uM) 
Fasudil 
 
 10.7 1.9 
HA1100 
 
 0.9 1.9 
H1152 
 
 0.002 0.012 
Y27632 
 
 0.14 0.3 
SB77207B 
 
 0.006 0.006 
T299 
 
319.36 1.675 0.115 
T303 
 
330.38 2.955 0.665 
T306 
 
399.48 6.845 3.735 
T343 
 
336.81 0.027 0.013 
T347 
 
373.33 Not 
Available 
Not 
Available 
T349 
 
326.78 Not 
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Available 
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Table 1. Structures, molecular weights, and kinase inhibition profiles, as available, for 
each of the ROCK inhibitors that was used during the study. All T- drugs are novel 
ROCK inhibitors synthesized at TGen.  
 
Commercially 
available drugs 
p-value Novel drugs p-value 
Fasudil 0.000043 T303 0.007 
H1152  T343 0.003 
Y27632 0.75 T299 0.9 
HA1100 0.6 T306 0.2 
Harmine 0.1 T347 0.5 
SB77 0.6 T349 0.8 
  T350 0.09 
Table 2. The difference between the p-tau to total tau ratio of H4-tau cells treated with 
each drug at LD-10 dosage in comparison to H4-tau cells treated with vehicle over a 96 
hour time course. The p-value is determined via a pairwise t-test. 
 
 Fasudil Y27632 T343 T299 
3, 6, 12, 24, 36 
hr 
MAPT    
6, 12 24, 36 hr SOX6   IL11, ESM1 
12, 24, 36 hr IGFBP3, 
TMEM100, 
PTGER4 
  SPRY2, 
SLC16A6, 
IL24, IHHBA 
3, 6, 12 hr   AHRr, 
SERPINB2, 
TFAP2C, GDA 
 
3, 6, 12, 24 hr   CPY1B1  
6, 12, 36 hr  ANKRD1, 
CPA4 
  
Table 3. Significant changes in expression levels in H4-tau cells after treatment with 
ROCK inhibitors Fasudil, Y27632, T343, or T299. Time points included in the study are 
3, 6, 12, 24, and 36 hours.  
 
 Fasudil – 3xTg Y27632 – 3xTg Fasudil – 
Wild-type 
Y27632 – 
Wild-type 
Radial arm 
water maze (10 
months) 
No change Reference 
memory 
impaired 
Reference 
memory 
improved 
No change 
Morris water 
maze (12 
months) 
No change No change No change No change 
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Fear 
Conditioning 
(15 months) 
Increased 
freezing 
No change Increased 
freezing 
No change 
p-tau No change – 
WB 
Significantly 
better – IHC 
No change N/A N/A 
Aβ Significantly 
better – ELISA 
No change – 
IHC 
Significantly 
worse, soluble 
Aβ42 only – 
ELISA 
No change – 
IHC 
N/A N/A 
Table 4. The summary of results for the in vivo experiments. Overall, Fasudil treatment 
improved learning and memory results in wild-type mice. Fasudil treatment did not lead 
to changes in learning and memory in 3xTg-AD mice until the final behavioral 
experiment. Y27632 treatment did not cause a change in learning and memory in either 
3xTg-AD mice nor in wild-type mice. Fasudil treatment decreased both p-tau and Aβ, 
although results vary based on testing method. Y27632 treatment did not change p-tau or 
Aβ levels, except for soluble Aβ42 levels, which were decreased. 
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APPENDIX B  
FIGURES 
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Figure 1. The ratio of p-tau to total tau for each drug, and water, treatment across all 
time-points. The water treatment led to a fairly stable ratio nearing 0.5, which is similar 
to many of the drug treatments. Notably, Fasudil and T343 remain closer to a ratio of 0.4.   
 
 
Figure 2 
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The p-tau to total tau ratio for all drugs at the LD-10 dosage. Most drug treatment did not 
lead to significant differences in the p-tau to total tau ratio. However, Fasudil, T303, and 
T343 treatments resulted in a significantly lower p-tau to total tau ratio.  
 
 
Figure 3.  
The ptau to total tau ratio for all drugs at the LD-10 dosage, using loess plotting to show 
the trendlines for the ratio. The lines for Fasudil and T343 treatment remain lower than 
the line for water treatment.  
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Figure 4.  
Fasudil-treated H4-tau cells had a significantly reduced p-tau to total tau ratio at a low 
dosage in comparison to water-treated cells.  
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Figure 5.  
Y27632-treated H4-tau cells did not have a significant effect on the p-tau to total tau ratio 
at a low dosage, in comparison to water-treated cells. 
 
 
Figure 6.  
T343-treated H4-tau cells had a significantly reduced p-tau to total tau ratio at a low 
dosage, in comparison to water-treated cells. 
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Figure 7.  
T299-treated H4-tau cells did not have a significantly different ratio of p-tau to total tau 
at a low dosage, in comparison to water-treated cells. 
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Figure 8.  
The ratio of p-tau to total tau after treatment by Fasudil, Y27632, T343, and T299 at a 
low dosage are shown in comparison to treatment by water. Fasudil and T343 treatment 
decrease the ratio, while Y27632 and T299 do not cause a significant difference over the 
time course. However, Y27632 treatment leads to a significant increase at the final time 
point. 
 
 
Figure 9 
The ratio of p-tau to total tau after treatment by Fasudil, Y27632, T343, and T299 at a 
high dosage are shown in comparison to treatment by water. Treatment by Fasudil, 
Y27632, and T343 all lead to a significant decrease in the ratio across the time course, 
while Y27632 leads to a significant increase. 
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Figure 10. 
High dosage Fasudil treatment in H4-tau cells led to a significant decrease in the 
expression levels of MAPT mRNA in comparison to water treatment over the entire time 
course. No other drug treatment, or DMSO treatment, led to a significant difference in 
MAPT mRNA at any time point. 
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Figure 11 
Fasudil treatment in 3xTg-AD mice did not have a significant effect on the number of 
total incorrect entries over the course of Day 2, indicating that Fasudil does not lead to 
changes in reference memory at 10 months of age for 3xTg-AD mice. 
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Figure 12 
Fasudil treatment in wild-type mice led to a significant decrease in the number of total 
incorrect entries over the course of Day 2, indicating that Fasudil improves reference 
memory in wild-type mice at 10 months of age.  
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Figure 13 
Y27632 treatment in 3xTg-AD mice led to a significant increase in total number of 
incorrect entries across Day 2, indicating that Y27632 impairs reference memory at 10 
months of age in 3xTg-AD mice. There were also significant differences during two 
specific trials on Day 2: trial 18 and 29. 
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Figure 14 
Y27632 treatment in wild-type mice led to no significant difference in the total number of 
incorrect entries on Day 2, indicating that Y27632 leads to no changes in reference 
memory at 10 months of age in wild-type mice. 
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Figure 15 
Fasudil treatment in 3xTg-AD mice did not lead to a significant difference in the number 
of re-entries into the incorrect arm over the course of Day 2, indicating that Fasudil does 
not have an effect on working memory at 10 months of age in 3xTg-AD mice. However, 
there was a significant decrease in the number of incorrect entries during one trial (Trial 
21), indicating that perhaps there is a trend toward an improvement. 
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Figure 16 
Fasudil treatment in wild-type mice did not lead to a significant difference in the number 
of re-entries into the incorrect arm over the course of Day 2, indicating that Fasudil does 
not influence working memory at 10 months of age in wild-type mice.  
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Figure 17 
Y27632 treatment in 3xTg-AD mice did not lead to a significant difference in the number 
of re-entries into an incorrect arm over the course of Day 2, indicating that Y27632 does 
not influence working memory at 10 months of age in 3xTg-AD mice. However, Y27632 
significantly increased the number of incorrect re-entries during three trials (18, 22, and 
29) indicating that there may be a trend toward an impairment in working memory. 
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Figure 18 
Y27632 treatment in wild-type mice led to no significant differences in the number of re-
entries into incorrect arms during Day 2, indicating that Y267632 does not affect working 
memory at 10 months of age in wild-type mice.  
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Figure 19. 3xTg-AD mice show no overnight retention impairment. 
There is no significant difference in overnight retention for any groups, except for 
Y27632-treated 3xTg-AD mice and vehicle-treated wild-type mice, indicating that 
treatment does not affect overnight retention at 10 months of age.  
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Figure 20. Treatment does not affect total swim distance in 3xTg-AD mice. 
On Day 3, Y27632-treated 3xTg-AD mice swam a significantly shorter distance than 
vehicle-treated mice before reaching the platform, and Fasudil-treated mice trended 
toward a shorter distance, indicating that these drugs may have some effect on reference 
memory at 12 months of age. There were no other significant differences on the other 
days, indicating that this effect is not robust. 
 
 
Figure 21. Treatment does not affect total swim distance in wild-type mice. 
On Day 4, Y27632-treated mice swam a significantly shorter distance than vehicle-
treated mice before reaching the platform, indicating that Y27632 may have some effet 
on reference memory at 12 months of age. There were no other significant differences on 
the other days, indicating that this effect is not robust. 
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Figure 22. 3xTg-AD mice show no overnight retention impairment. 
The distance swam by each of the 3xTg-AD treatment groups for the final trial and first 
trial of each day shows that none of the groups displayed significant differences in 
overnight retention on any day. 
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Figure 23. Wild-type mice show no overnight retention impairment. 
The distance swam by each of the wild-type treatment groups for the final trial and first 
trial of each day shows that none of the groups displayed significant differences in 
overnight retention on any day. 
 
 
 
Figure 24. Treatment does not improve number of platform hits during probe trial. 
During the probe trial, treatment by either Fasudil or Y27632 does not change the number 
of times 3xTg-AD mice or wild-type mice pass over the area the platform was in 
previous trials. 3xTg-AD mice pass over the platform space significantly less than wild-
type mice. 
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Figure 25. Time in platform quadrant not affected by group or treatment. 
There is no significant difference in the amount of time, within a 60 second timeframe, 
during which any group of mice spent in the platform quadrant. 
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Figure 26. Time in opposite quadrant not affected by group or treatment. 
There is no significant difference in the amount of time, within a 60 second timeframe, 
during which any group of mice spent in the quadrant opposite the platform quadrant. 
 
 
Figure 27. Ratio of time spent in opposite vs platform quadrant not affected by 
group or treatment. 
The average amount of time spent in the platform quadrant in comparison to the opposite 
quadrant. In wild type vehicle-treated mice, there is a more comparable difference 
between the amount of time. The 3xTg-AD mice do not have as comparable a difference 
between the amount of time in the platform vs opposite quadrant. However, this is not a 
significant ratio. 
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Figure 28. Fasudil treatment improves memory in 3xTg-AD mice at 15 months. 
Fasudil-treated 3xTg-AD mice freeze for a longer time per freeze event  in comparison to 
vehicle-treated 3xTg-AD mice, indicating that Fasudil treatment increases memory at 15 
months of age in 3xTg-AD mice. 
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Figure 29. Fasudil treatment improves memory in wild-type mice at 15 months. 
Fasudil-treated wild-type mice freeze for a longer time per freeze event  in comparison to 
vehicle-treated wild-type mice, indicating that Fasudil treatment increases memory at 15 
months of age in wild-type mice. 
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Figure 30. Y27632 treatment does not affect memory in 3xTg-AD mice at 15 
months.  
Y27632-treated 3xTg-AD mice do not have a significantly different freeze duration in 
comparison to vehicle-treated mice, indicating no effect on memory at 15 months of age.  
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Figure 31. Y27632 treatment does not affect memory in wild-type mice at 15 
months. 
Y27632-treated wild-type mice do not have a significantly different freeze duration in 
comparison to vehicle-treated mice, indicating that Y27632 does not have an effect on 
memory at 15 months of age. 
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Figure 32. No difference in freeze count with Fasudil treatment in 3xTg-AD mice. 
There is no significant difference in the number of times Fasudil-treated and vehicle-
treated 3xTg-AD mice froze on Day 2.  
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Figure 33. No difference in freeze count with Fasudil treatment in wild-type mice. 
There is no significant difference in the number of times Fasudil-treated and vehicle-
treated wild-type mice froze on Day 2.  
 
 
Figure 34. No difference in freeze count with Y27632 treatment in 3xTg-AD mice. 
There is no significant difference in the number of times Y27632-treated and vehicle-
treated 3xTg-AD mice froze on Day 2. 
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Figure 35. No difference in freeze count with Y27632 treatment in wild-type mice. 
There is no significant difference in the number of times Y27632-treated and vehicle-
treated wild-type mice froze on Day 2.  
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Figure 36. Western blot wells loaded equally. 
Actin levels are not significantly different between groups, indicating that significant 
differences with other antibodies are not an artifact of unequal loading. 
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Figure 37. Fasudil decreases APP in 3xTg-AD mouse hippocampus. 
Fasudil-treated, but not Y27632-treated, 3xTg-AD mice have a significantly decreases 
level of APP in the hippocampus. 
  
 
Figure 38. APP C-terminal levels not affected by treatment. 
Neither Fasudil-treated nor Y27632-treated 3xTg-AD mice had a significant difference in 
APP C-terminal fragments in the hippocampus. 
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Figure 39. Total tau levels not affected by treatment. 
Neither Fasudil nor Y27632 treatment significantly changed the level of total tau in the 
3xTg-AD hippocampus. 
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Figure 40. p-tau levels not affected by treatment. 
Neither Fasudil nor Y27632 treatment significantly changed the level of p-tau at the 
Ser202 residue in the 3xTg-AD hippocampus. 
 
 
Figure 41. Y27632 treatment increases p-tau to total tau ratio. 
Y27632 treatment led to a significant increase in the p-tau (Ser202) to total tau ratio in 
comparison to vehicle-treated 3xTg-AD mice, indicating an increase in pathology. There 
was no significant difference between Fasudil-treated and vehicle-treated mice. 
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Figure 42. Fasudil treatment decreases insoluble Aβ40. 
Fasudil-treated mice, but not Y27632-treated mice, had a significantly decreased level of 
insoluble Aβ40 in comparison to vehicle-treated mice, indicating that Fasudil improves 
pathology. 
  
  110 
 
Figure 43. Insoluble Aβ42 levels not affected by treatment. 
There is no significant difference in levels of insoluble Aβ42 between Fasudil- or 
Y27632-treated mice and vehicle-treated mice. 
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Figure 44. Fasudil treatment decreases soluble Aβ40. 
Fasudil-treated mice, but not Y27632-treated mice, had a significantly decreased level of 
soluble Aβ40 in comparison to vehicle-treated mice, indicating that Fasudil improves 
pathology. 
 
 
Figure 45. Y27632 treatment increases soluble Aβ42.  
Y27632 treatment significantly increases the level of soluble Aβ42 in comparison to 
vehicle treatment, indicating that Y27632 increases pathology. Fasudil treatment did not 
cause a significant change in soluble Aβ42.  
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Figure 46. Hippocampal Aβ42 not affected by treatment 
While neither Fasudil nor Y27632 treatment significantly change the level of Aβ42 seen 
in the hippocampus with IHC, Fasudil treatment trends toward a decrease with p = 0.055, 
indicating that there may be some improvement in the pathology. 
 
 
Figure 47. Representative images of IHC staining of hippocampal Aβ42. 
Each image represents its treatment group, and is the image with the median amount of 
staining, as represented by the box plot in Figure 46. Aβ in hippocampus of (a) vehicle-
treated mouse, (b) Fasudil-treated mouse, and (c) Y27632-treated mouse. 
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Figure 48. Cortex Aβ42 levels not affected by treatment. 
There is no significant difference in the level of Aβ42 staining in the cortex between mice 
treated with Fasudil or Y27632 in comparison to mice treated with vehicle. 
 
Figure 49. Representative images of IHC staining of cortex Aβ42. 
Representative staining images from IHC of cortex Aβ42. Each image represents its 
treatment group, and is the image with the median amount of staining, as represented by 
the box plot in Figure 46. A𝛽 in cortex of (a) vehicle-treated mouse, (b) Fasudil-treated 
mouse, and (c) Y27632-treated mouse. 
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Figure 50. Fasudil decreases p-tau levels (Thr205/Ser202). 
Fasudil treatment leads to a significant decrease staining using AT8, and antibody that 
stains for tau phosphorylated at residues Thr205 and Ser202. Y27632 treatment does not 
alter AT8 staining in comparison to vehicle treatment.  
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Figure 51. Representative images of IHC staining of p-tau. 
Representative staining images from IHC of phosphorylated tau (Ser202/Thr205). Each 
image represents its treatment group, and is the image with the median amount of 
staining, as represented by the box plot in Figure 48. Phosphorylated tau in the brain of a 
(a) vehicle-treated mouse, (b) Fasudil-treated mouse, and (c) Y27632-treated mouse.  
 
Figure 52. ROCK I and ROCK II expression levels do not differ between human AD 
and non-AD brain samples. 
ROCK I and ROCK II expression levels in human samples. Expression levels were 
compared between AD patients and non-diseased (ND) samples. Results are from whole 
expression profiling analysis performed with HumanHT-12_v4_BeadChip (Illumina) in 
97 AD vs 98 ND medial temporal gyrus samples. Data were normalized and analyzed 
with R package LUMI and p-values for differential expression analysis were corrected 
for multiple comparisons with FDR method. ROCK II shows two results due to two 
different probes in the chip. These were analyzed at the probe level as suggested by 
authors of R package LUMI.  
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LIST OF ABBREVIATIONS 
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AD – Alzheimer’s disease 
APP – Amyloid precursor protein 
PS1 – presinilin 1 
PS2 – presinilin 2 
Apolipoprotein E – APOE 
NFT – neurofibrillary tangle 
Aβ – amyloid-β 
CTF – C-terminal fragments 
MAPT – Microtubule Associated Protein Tau 
Ser – Serine 
Thr – Threonine 
ROCK – Rho-associated protein kinase 
SMOL – Small, chemically manufactured molecules 
ACE – Angiotensin-converting-enzyme 
CDK5 – Cyclin dependent kinase 5 
NSAID – Nonsteroidal anti-inflammatory drug 
MLC – Myosin light chain 
PTEN – Phosphotase and tensin homolog deleted on chromosome 10 
GSK-3β – Glycogen synthase kinase-3 β 
LIMK – LIM kinase 
H4-tau – H4 neuroglioma cells overexpressing four repeat tau (4R0N) 
3xTg-AD – Triple transgenic AD 
BCA – Bicinchroninic acid 
IHC – Immunohistochemistry 
ELISA – Enzyme-linked immunosorbent assay 
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Introduction: 
Alzheimer’s disease (AD) is a progressive neurological disorder and the most common 
form of dementia in the United States. AD is also the sixth leading cause of death in the 
United States. At this time, diagnosis only occurs after memory loss symptoms have 
become moderate to severe. Treatment must occur before these symptoms begin, as 
neuropathology begins and progresses for an estimated 15-20 years before this point. The 
AD field needs both new treatment options, coupled with early diagnostic tools, such as 
blood or cerebrospinal fluid biomarkers and neuroimaging assessments. This review aims 
to briefly explore new biomarkers and genetic risk factors and delve deeply into the future 
of nucleic acid-based diagnostic medicine for AD. 
 
Biomarkers: 
The National Institute of Neurological and Communicative Disorders and Stroke 
and the Alzheimer’s disease and Related Disease and Related Disorders Associations 
discussed the classifications and methods used for diagnostic testing of AD in 1984, and 
the guidelines have not been updated since then(McKhann et al., 1984). Diagnoses use 
neuropathological patterns and clinical testing methods in order to determine whether the 
patient falls under classifications of “possible”, “probable” or “definite” AD.  
Biomarkers are necessary to better classify and diagnose AD prior to disease onset. 
Present biomarkers are associated with AD post-onset, and are not capable of providing 
information prior to symptomatic pathology. However, those biomarkers are still useful for 
classification purposes for patients and their families in order to provide the framework for 
appropriate care of the patient, as well as for research purposes, allowing patients and their 
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families to enroll in AD-specific studies. In short, the biomarkers that exist today were 
designed to classify individuals into healthy versus diseased classes and were not 
necessarily developed to determine risk in an otherwise healthy individual. Movement 
toward this type of biomarker is important for longevity as treatment starting at the current 
diagnostic mark is not able to return patient brain function to baseline levels.  
Biomarkers must be predictable and should ideally be simple to supervise and 
inspect over the course of both prognosis and disease. While protein biomarkers have been 
attractive and highly studied for AD, and there have been a variety of promising 
possibilities, these potential biomarkers are complex due to the posttranslational 
modifications, sequence variations, and complications with development of high affinity 
and high sensitivity assay methods. Additionally, the protein biomarkers discovered thus 
far have also only been associated with AD after the disease onset, and thus would not be 
effective biomarkers for preventative medicine (Esteras et al., 2013; Harari et al., 2014; 
Ruiz et al., 2013; C. Wang et al., 2014). 
Nucleic acids – DNA and RNA – have significant potential as effective biomarkers 
for AD and other neurological disorders. They have the benefits of being stable and are 
able to be amplified during assay allow the signal to be increased for even the lowest 
expressed molecules (something that cannot be currently done for rare protein species). 
Additionally, the maturation of so-called next generation sequencing approaches has 
significantly improved our ability to assay nucleic acids in an entirely un-biased digital 
fashion, therefore, measurements are much more reproducible in other laboratory 
environments and have a dramatically expanded dynamic range when compared to 
microarray-based measurements of nucleic acids.   
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Nucleic acid biomarkers come in two main classes, those that are personalized and 
represent heritable risk factors (e.g. the DNA variants that were passed on to you by your 
mother or father in your germline genome) or those that represent markers of a change in 
physiology or development of a pathophysiology (e.g. circulating RNAs that may be 
released from the brain in response to the progression of AD-relevant pathology or site-
specific DNA methylation changes). 
 
Genetic risk factors: 
Genome wide association studies (GWAS) have been used to identify susceptibility 
loci for AD under the common disease-common variant hypothesis for approximately the 
last decade. Most studies on late onset Alzheimer’s disease (LOAD) have been performed 
on non-Hispanic white people of European ancestry. The International Genomics of 
Alzheimer’s Project combined all non-Hispanic white data sets, leading to 12 additional 
susceptibility loci and 13 candidate loci being found through this study.  
The Apolipoprotein E gene (APOE) has been established as a susceptibility gene 
for LOAD, with an increased risk of 12-fold for ε4 homozygotes(Chen et al., 2007; Reiman 
et al., 2007). This makes up approximately 25% of the estimated heritability of ~80% for 
LOAD. While a large portion of the heritability risk is accounted for by APOE, this still 
leaves room for other genetic factors that could modify the risk of LOAD(Seshadri et al., 
2010). Over 1200 papers have claimed or refuted an association between AD and a variety 
of putative risk genes, with often contradictory results. Many of these studies are not 
replicated, likely due to small genetic effects and low powered data sets. However, 20 other 
susceptibility loci have been identified with replicable results including SORL1, CLU, 
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PICALM, ABCA7 and BIN1(Harold et al., 2009; Hollingworth et al., 2011; J.-C. Lambert 
et al., 2009; J. C. Lambert et al., 2013; Naj et al., 2011). Many of these loci have been 
associated with immune function, and are likely to be found in other disease states, and 
while they may be risk factors functioning as decreased immune function or overactive 
immune function leading to glial overactivity and increased neurodegeneration, they may 
not be useful for AD risk assessment. However, some of the susceptibility loci identified 
continue to be of interest to the AD community due to their function. SORL1 and ABCA7, 
for example are involved in APP processing and trafficking(Andersen et al., 2005, 2006; 
Mack, Townsend, Beljanski, & Tew, 2007; Spoelgen et al., 2006; Yin, Yu, & Tan, 2014). 
Single nucleotide polymorphism (SNP) variants of PICALM have been highly associated 
with AD, but not with other neurodegenerative disease. Overexpression of normal 
PICALM increases the internalization of APP and the formation of Aß42 and amyloid 
plaques(Xiao et al., 2012). CLU expression has been shown to be upregulated in AD patient 
brains. CLU mutations have also been associated with LOAD, as well as with APOE allele 
ε4(Lidstro, 1998; McGeer, Kawamata, & Walker, 1992). BIN1 mutations may be a risk 
factor for LOAD through the trafficking of APP(Carrasquillo et al., 2011). Presently, it is 
possible to screen an individual’s germline genome and quantitate their heritable risk for 
developing AD, however, even with the best models we can likely only explain half of 
their overall genetic risk, therefore, more work is needed to fully characterize the remaining 
factors in our genome that are linked to altered AD risk.  
Oxidation levels of RNA may be used as a biomarker of AD, although it is 
decidedly non-specific. DNA is oxidized and repaired under non-disease states; however, 
extensive RNA oxidation may be a mechanism for disease development. RNA oxidation 
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results in ribosomal stalling and dysfunction, and can be identified through those 
means(Poulsen et al., 2012). However, studies have not yet parsed out the differences in 
RNA oxidation that may occur between different neurodegenerative diseases and other 
diseases as well, therefore the question remains regarding the specificity of such a marker 
for AD in particular.  
Another route through which mRNA can be studied in the context of AD is through 
RNA editing. Adenosine to inosine (A to I) RNA editing occurs within precursor mRNA, 
and is prevalent in the human brain. It occurs at both the protein-coding and noncoding 
regions of the RNA(Bass, 2002; Valente & Nishikura, 2005). A to I RNA editing has been 
shown to differ between controls and patients with amyotrophic lateral sclerosis, providing 
a possible mechanism of action for neuronal death(Kwak & Kawahara, 2005). Few studies 
have examined RNA editing in AD patients specifically, although one has found a decrease 
in RNA editing in the prefrontal cortex of AD patients(Akbarian, Smith, & Jones, 1995) 
and another has found differences in RNA editing between AD patient hippocampus and 
control hippocampus(Gaisler-Salomon, Kravitz, & Feiler, 2014). The usefulness of this 
approach as a biomarker tool remains to be seen, as much of the work to date has been 
conducted on autopsy derived material. 
Profiling of blood-based buffy coat derived RNA has been used to examine 
multiple types of human disease with limited success. The same case can be made for AD. 
We are not certain as to why this approach has yielded limited success as a biomarker, 
however one could hypothesize that the gene expression patterns present within circulating 
nucleated cells is not significantly altered enough – especially in the early stages of 
neurological disease – to result in a biomarker with appreciable sensitivity and specificity. 
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A modern example of a blood-based signature can be found in the AclarusDx™ 
assay(Fehlbaum-Beurdeley et al., 2012). This approach examines 136 known genes 
involved in multiple types of biological processes with the hope of assigning an individual 
to either an AD case or control group. The assay is reported to have a sensitivity of 81% 
and a specificity of 67%, however, this biomarker panel is focused on aiding in the 
diagnosis of AD once already suspected by a clinician – it is not designed to determine AD 
risk before symptom onset. 
microRNAs (miRNA) have been of high interest to AD and other neurological 
disease researchers for several years due to their demonstrable stability outside of the cell 
and identification of them packaged in extracellular microvesicles. miRNAs are non-
coding RNA containing approximately 22 nucleotides and are recognized as critical 
regulators of gene expression. Notably, individual miRNA species can target several 
different transcripts, thereby providing a mechanism of action that could perturb entire 
signaling pathways through the altered expression of one miRNA. miRNA have been found 
in extracellular fluids such as plasma, serum, urine, and saliva, while changes in 
extracellular miRNA have been observed and studied in the instance of cancer, 
cardiovascular disease, and injury(Hanke et al., 2010; Mitchell et al., 2008; Park et al., 
2009; Zubakov et al., 2010). Similarly, this deregulation of miRNA has also been 
associated with degenerative diseases such as AD(Cogswell et al., 2008; Geekiyanage, 
Jicha, Nelson, & Chan, 2012; Lukiw, 2007). Some hypothesize that extracellular miRNA 
are found in healthy individuals through the circulating blood cells, but that in illness and 
injury the affected tissue(s) releases miRNA as well.  Thus, the miRNA released by the 
affected tissue, such as the brain in AD, could serve as an effective biomarker.  
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The brain has been found to have the highest levels of tissue specific miRNA(Babak, 
Zhang, Morris, Blencowe, & Hughes, 2005). miRNA extracted from brain tissue that have 
been found to be dysregulated in AD cases include miR-9, miR-20a, and miR-132(Hébert 
et al., 2009; Hébert, Sergeant, & Buée, 2012; Makeyev, Zhang, Carrasco, & Maniatis, 
2007). However, brain tissue biomarkers are not useful in clinical diagnoses, and 
extracellular miRNA biomarkers are necessary. Extracellular miRNA that originated in the 
brain can be found in the CSF, blood, saliva, and urine(Baraniskin et al., 2012; Hunter et 
al., 2008; Ogawa, Taketomi, Murakami, Tsujimoto, & Yanoshita, 2013; Patel et al., 2011; 
Qi, Wang, Katayama, Sen, & Liu, 2013). Extracellular miRNA can be an effective 
biomarker because they are protected from degradation by binding to RNA binding 
proteins, or are contained in membrane derived microvesicles such as exosomes(Arroyo et 
al., 2011; Mitchell et al., 2008; Vickers & Remaley, 2012). While circulating miRNA have 
been shown to be useful biomarkers in cancer studies, using them for AD may not be as 
fruitful because the mechanism and the level at which brain specific miRNA pass through 
the blood brain barrier is unknown. However, it is known that highly abundant brain 
specific miRNA are found in the CSF, blood, and urine. Therefore, there is a possibility 
that circulating miRNA will be an effective biomarker for AD. A notable shortcoming to 
these efforts may lay in the current inability to identify and purify microvesicles that are 
released from the brain – distinguishing those microvesicles from others derived from non-
disease relevant tissues would theoretically aid in the increase of disease biomarker signal 
relative to the healthy tissue noise. 
CSF is perhaps the most relevant, albeit invasive to obtain, source of biomarkers 
for AD and other neurodegenerative diseases, as it is produced in close proximately and 
  128 
surrounds the organ of interest. The most commonly used platform to measure miRNA 
levels in CSF is qRT-PCR; however, more recently, next generation sequencing has been 
utilized and optimized for miRNA quantification. qRT-PCR has allowed for the discovery 
of 60 miRNA that are significantly altered in the CSF of patients with AD, as compared to 
healthy elderly control CSF. These miRNA were associated with changes in the immune 
system, however, and are therefore likely linked to general neurodegeneration rather than 
to AD specifically. Other studies have also attempted to find differential expression of 
miRNA in CSF between AD patients and controls; however, the upregulation and 
deregulation of the miRNA found in each study were not replicated in subsequent 
studies(Alexandrov et al., 2012; Cogswell et al., 2008; Lehmann et al., 2012; Lukiw, 
Alexandrov, Zhao, Hill, & Bhattacharjee, 2012). These contradicting results could be due 
to methodological differences in quantification approach—the studies used either 
microarrays, qPCR, or target candidate miRNA approaches.  
Next generation sequencing is a potent technique for quantifying differential 
expression of miRNA between AD patients and controls. Brain specific miRNA dilutes in 
the circulatory system, leading to a greater signal to noise ratio when compared to 
quantification of miRNA in the brain tissue(Cheng, Quek, Sun, Bellingham, & Hill, 2013). 
While blood biomarkers would be a minimally invasive and simple diagnostic test, few 
studies have profiled miRNA differences in AD patients compared to controls. However, 
these studies have found a number of brain specific miRNA down regulated in the blood 
of AD patients, as well as miRNA that were upregulated in patients with early AD 
symptoms(Geekiyanage et al., 2012). Further studies could include exosome separation 
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from the blood in order to find differential expression specific to exosomes, as has been 
done with plasma and serum.  
An attractive minimally invasive and very cost effective clinical diagnostic 
biospecimen is urine. Circulating extracellular RNA is released into the urine through renal 
epithelial cells bound to RNA binding proteins or packaged into microvesicles. RNA in 
urine has been used for diagnosis in bladder or prostate cancers(Hanke et al., 2010); 
however, the same techniques may not be effective for neurodegenerative diseases such as 
AD because the cells in urine are highly concentrated from hematologic, renal, or urothelial 
origin. Cell-free urine may be useful; however, separating the cells from the urine may also 
remove miRNA from tissues outside the excretory system. Exosomes may be the most 
effective solution for miRNA studies from urine samples.  
 
Epigenetics 
Another possible risk factor involves the transient, reversible changes to chromatin, and 
the modifications these changes can have on gene expression and transcription activity. 
These changes are classified as epigenetics, and include chromatin remodeling, histone 
modification, and DNA methylation, among other DNA alterations. Epigenetics could 
have an effect on the risk of developing AD. Genetic risk factors can play a large role in 
the disease; however, even human monozygotic twins differ in developing AD(Brickell et 
al., 2007). Environmental risk factors must have a significant effect on the disease and 
epigenetics allows environmental factors to influence genetic expression without altering 
DNA sequence. Epigenetic changes repress or silence the expression of specific genes, or 
release that repression, enhancing gene expression. 
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DNA methylation has been investigated in post-mortem brain tissue in both AD 
mouse models and human AD patients(Brohede, Rinde, Winblad, & Graff, 2010; Cadena-
Del-Castillo et al., 2014; Chouliaras et al., 2013; Coppieters & Dragunow, 2011; Mastroeni, 
McKee, Grover, Rogers, & Coleman, 2009; Siegmund et al., 2007). Genetic risk may 
partially explain the DNA methylation differences found in these studies; however, GWAS 
studies have not found differences in genes linked to DNA methylation between controls 
and AD patients. There has been evidence for environmental factors such as diet having an 
effect on DNA methylation. For example, a study showed that folate deficiency in late life 
is associated with an increased percentage of AD, and that vitamin B treatment in AD 
patients with low baseline folate levels benefit the patients(Hinterberger & Fischer, 2013). 
Because these epigenetic changes would not be available until later in life, they may not 
be as useful as a biomarker for preventative therapeutics; however, they could be used as 
a risk assessment tool for making lifestyle changes in the older population.  
While twin studies would be an excellent method to parse out the genetic and 
environmental effects of AD, especially with regards to epigenetics, it is difficult to find 
pairs of monozygotic twins within which at least one twin has AD. One pair of 
monozygotic twins that was discordant for AD was studied for methylation differences in 
the temporal neo-cortex and the superior frontal gyrus. In the AD twin, both regions had 
significantly decreased global methylation levels. However, the twins had no differences 
in methylation in the cerebellum, which is largely unaffected by AD(Mastroeni et al., 2009). 
This study demonstrated that epigenetics may play a role in the development of AD.  
One study used the triple transgenic model of AD (3xTg-AD) in order to assess 
methylation changes in both an early age (pre-AD) and a late age (post-AD) AD model and 
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confirm differences within the two categories. Due to the difficulty in finding more 
monozygotic twin pairs discordant for AD, an animal study was necessary to confirm the 
results. The study both confirmed the decrease in methylation and added that there were 
markers for demethylation as the mice aged. They also found that young 3xTg-AD mice 
had increased levels of demethylation that matched aged wild type mice, indicating early 
aging occurring in mice with AD(Cadena-Del-Castillo et al., 2014). This study 
demonstrates that epigenetic changes that could be risk factors for AD may occur earlier 
in life, and therefore may be risk factors to consider at an early age, or could even be used 
as biomarkers. 
DNA methylation, as a risk factor, is an interesting and exciting line of study as it also has 
potential as a biomarker. Statistical methods for analyzing DNA methylation as a 
biomarker have been produced(Alonzo & Siegmund, 2007) and biomarkers through DNA 
methylation have been implicated and are currently being pursued in different cancer 
studies(Kan, Liou, & Wang, 2014; Winham et al., 2014).  
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Future Perspective: 
 In the next five years, AD treatment is likely to go through a significant 
metamorphosis because of increasing assessment of “prevention” trials. If successful, these 
trials will guide the use of effective and safe medications in individuals who do not yet 
demonstrate dementia but are at elevated risk for the disease. This strategic approach to 
AD, and hopefully other progressive degenerative neurological diseases, is important not 
only to the specific field of AD therapeutics but also for the potential treatment of other 
slow onset disorders. It is very likely that the therapeutics, when administered earlier in the 
course of the disease than ever before, will demonstrate a positive effect. 
 Unfortunately, how early pending AD is diagnosed or how early personalized risk 
is reliably assessed remains a problem in society. This raises issues and is important 
because it is unlikely that the best preventative medicines will come without side effects 
and/or significant cost to the patient. Therefore, at least in the beginning stages of the 
prevention era, decisions will need to be made regarding the individuals who utilize 
prevention therapeutics versus those who do not. Imaging- and genomics-based biomarkers 
will likely contribute significantly to fill this void. The use of amyloid imaging has largely 
shown to be beneficial in the diagnosis of AD and it can also help assess risk in 
presymptomatic individuals. Many biotechnology and pharmaceutical companies are also 
working on developing tau-based imaging agents. However, imaging tests are not cost 
effective, they are data intensive, and expose the patient to some risk associated with the 
agent itself. Although nucleic acid biomarkers, as reviewed here, are still in their infancy, 
the field is advancing rapidly, with novel approaches and focus on extracellular RNA 
measurements in easy to obtain biofluids (like saliva and urine) and the use of next 
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generation sequencing, to both quantitate and sequence the RNA/DNA analyses. We 
believe it is likely that a blood-based nucleic acid focused biomarker test for AD will 
mature in the coming five years, with urine and/or saliva tests developing soon after. It is 
likely that these tests will need troubleshooting once developed, but they will act as an 
initial screen in determining if an individual had a tau or amyloid imaging test prior to 
starting prevention therapy. In short, we foresee the approval of at least one prevention 
therapeutic in the coming decade and the likely use of combined biomarker approaches – 
imaging and nucleic acid – to determine if an individual should or should not be prescribed 
AD alleviating medicine.  
 Lastly, we recognize that innovative approaches are needed in conducting human 
studies. Many of the trials in the AD field are small and too focused to provide a complete 
picture of the potential patient or even healthy human being. To address this, several groups, 
ours included, have resorted to recruiting and studying individuals using the internet. Our 
study, MindCrowd (at mindcrowd.org) seeks to recruit one million healthy volunteers to 
take a ten-minute episodic memory test. To date, over 30,000 people have completed the 
study, providing us answers to over 20 demographic questions. We have had at least one 
participant from over 150 countries in the world. Through this study, we are not only able 
to examine the most common demographics and their influence on our cognitive task, but 
we can also examine combinations of factors, including rare events such as the co-
occurrence of early onset hypertension and a first degree relative with AD, allowing us to 
tease out how they might work together to influence cognition. Importantly, these large 
surveys enable us to identify those individuals who are significant outliers (think of a 60 
year old who scores perfectly on our episodic memory task). These test takers represent 
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less than 0.5% of their respective age group and therefore may harbor novel genetic 
changes that enhance their cognition or protect them from some aging effects. Moreover, 
large internet-based studies may be the only way to identify these rare genetic changes of 
large effect. 
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